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C h ro n i c  H BV in f ec t io n  i s  p rev a l en t  i n  In d i an  p op u l a t i on  w i t h  
p r ev a l en ce  r a t e  o f  2 - 4 % (1 ) .  I t  i s  w e l l  k no wn  t o  cau s e  ch r o n i c  
h ep a t i t i s ,  ch ro n i c  l i v e r  d i s eas e  an d  h ep a to ce l lu l a r  c a r c i no m a  ( HCC )  
( 2 ) .  I t  i s  t h e  m os t  co mm on  caus e  o f  l i ve r  c i r rh os i s  an d  hep a to ce l lu l a r  
c a r c in om a in  m os t  p a r t s  o f  As i a  (3 ) .  I t  i s  a  g l ob a l  h ea l th  i s s u e  r es u l t i n g  
i n  s i gn i f i c an t  ann ua l  mo r t a l i t y  w o r ldw i de .  S tu d i es  f rom  In d i a  h av e  
s ho w n p r edo min an ce  o f  G en o t yp e  D  and  A  ( 1 , 4 , 5 , 6 ) .  P a t i en t s  w i t h  h i gh  
v i ra l  cou n t s  an d  p e r s i s t en t  i n f l am m at io n  ( e l ev a t ed  l i v e r  enz ym es  o r  
h i s t o pa th o lo g i ca l l y)  h av e  mo r e  in c id en ce  o f  d i s eas e  p ro gr e s s io n  and  
r e l a t ed  co mp l i ca t i on .  Bo th  e  an t i gen  an d  su r f ace  an t i gen  a r e  p r od u ced  
b y H ep a t i t i s  B  v i ru s .  T hes e  mar k er s  a re  us e f u l  i n  d i agn os i s  and  
m an agem ent  o f  p a t i en t s  w i th  h ep a t i t i s  B  . H BeA g s e ro con ve r s i on  i s  
i mp or t an t  i n  n a tu r a l  h i s t o r y o f  CH B pa t i en t s  as  i t  i nd i ca t e s  d ec l in e  in  
v i ra l  r ep l i c a t i on  and  s ub s eq u en t  r emi s s io n  o f  l i v e r  d i sea se . 20 - 30  % 
s e r o co nv e r t ed  p a t i en t s  m ay h av e  r eac t iv a t io n  o f  h ep a t i t i s  B  v i r us  w h i ch  
m a y p r o gr e s s  t o  E  an t i gen  n ega t iv e  ch r o n i c  h ep a t i t i s .  Su ch  pa t i en t s  a r e  
s t i l l  p r on e  fo r  d ev e l op ment  o f  ch ro n i c  l i v e r  d i s ea s e  an d  HCC  (7 ) .  
 
 T he r e  a r e  4  p h as es  i n  t he  n a tu r a l  h i s to r y o f  ch r on i c  H BV  in f ec t i on :  
i mmu no to l e r an t  ( IT ) ,  im mu no c l ea r an ce  ( IC ) ,  l o w r ep l i c a t iv e  ( LR )  an d  
E  an t i gen  n ega t iv e  h ep a t i t i s  (E N H ) . Thes e  p h as es  a re  d e f in ed  b y 
s p ec i f i c  v i r o lo g i ca l ,  b io ch emi ca l  an d  se r o l o g i ca l  ch ar ac t e r i s t i c s  
i n c lu d i n g  l i v e r  enzm es , D NA  l oads ,  e  A n t i gen  s t a t us .  Th es e  p h as es  a r e  
n o t  n eces s a r i l y  s equ en t i a l  and  d o  no t  o ccu rs  i n  a l l  i nd i v id u a l s .  
A n t iv i r a l  t h e rap y i n c lu d in g  nu c l eos ( t ) i d e  i nh ib i to r s  o r  i n t e r f e r on  
t h e r ap y can  l e ad  t o  b i o ch em i ca l  and  v i r o lo g i ca l  r em is s io n .  R ecen t  
ev id ence  s u gges t s  t h a t  r es po ns e  to  an t i v i r a l  t h e r ap y i s  e x t r ap o l a t ed  in t o  
r ed u ced  in c i d en ce  o f  ch r on i c  l i v e r  d i sea s e  and  h ep a t oce l lu l a r  
c a r c in om a ( 8 ) .  In t e r f e r on  t he r ap y i s  e f f ec t i v e  on l y i n  3 0 -4 0 % o f  
p a t i en t s  and  i t s  u s e  i s  l i mi t ed  b y s i d e  e f f ec t s  and  h i gh  cos t s  ( 9 ) .  
N u c l eos ( t ) i d e  an a logu e  th e r ap y  r equ i re s  l i f e l on g  th e r ap y w i t h  
em er gen ce  o f  d r u g  r e s i s t an t  mut an t  v i ru s .  H en ce  th e r e  i s  n eed  f o r  
d ev e l opm ent  o f  m ar k e rs  o f  r e sp on s e  bo th  b e f o r e  t r e a tm en t  an d  a f t e r  
t r e a tm en t .  Th e  cu r ren t  go l d  s t and a rd  fo r  m on i to r i n g  t he r ap y i n  c l i n i ca l  
s e t t i n gs  i s  qu an t i t a t i v e  H BV  D N A  es t im at io n  b y r ea l  t im e  p o l ym er a s e  
ch a in  r eac t io n  (PCR )  t e ch n iq u e  w hi ch  h as  h i gh es t  s ens i t i v i t y  an d  
r ep r od uc ib i l i t y .  H ow ev e r  qu an t i t a t i ve  H BV  D NA  es t im at io n  i s  co s t l y  
an d  un av a i l ab l e  i n  s om e  p l aces .   
                                               
B l um b er g  d i s co ve red  H Bs A g an d  s i nce  th en  i t  i s  u s ed  as  h a l lm a rk  o f  
H BV  i n f ec t i on .  In i t i a l  t e s t s  fo r  qu an t i f i c a t io n  o f  s u r f ace  an t i gen  w e r e  
cu mb e rs om e,  l abo ur  i n t ens i v e  and  re s t r i c t ed  t o  r e sea r ch  l ab o r a to r i e s .  
M o r eo v er  i n  19 80 s  t h e r e  was  no  t h e r apy av a i l ab l e  fo r  H B V  in f ec t i on .  
N o tab l y,  ad van ces  h av e  b een  m ad e  r ecen t l y i n  t h e  d ev e lop m ent  o f  
q u an t i t a t i v e  s u r f ace  an t i gen  as s a ys  w h i ch  h ave  a l l o w ed  b e t t e r  v i r a l  
r ep l i c a t i on  mo ni to r i n g .  Th i s  i n t e r e s t  i n  s u r face  an t i gen  qu an t i f i c a t io n  
w as  d e r i ved  f r om fac t  t h a t  i t  i s  f ou nd  t o  b e  i n  go o d  co r r e l a t i o n  wi th  
i n t r a -h ep a t i c  cov a len t l y c l o s ed  c i r cu l a r  ( c cc )  DN A ,  t h e  re s e r vo i r  o f  
H BV  i n f ec t i on  an d  t em pl a t e  fo r  H BV  rep l i c a t i on  i ns i d e  hep a to cyt e  
n u c l e i  (1 0 , 11 ) .  R edu c t io n  in  c cc  DN A  a f t e r  an t i v i r a l  t h e rap y i s  
p r ed i c t o r  o f  s us t a ined  v i r a l  r es po ns e  (1 2 )  .C han ges  in  su r f ace  an t i gen  
l ev e l s  b e fo r e  an d  a f t e r  an t i v i r a l  t h e r ap y co r r e l a t e  w e l l  wi th  c cc  D N A.   
 
In  r e cen t  yea r s  m any s t u d i es  h av e  b e ing  co nd u c t ed  u s i n g  s u r face  
an t i gen  qu an t i f i c a t i on  fo r  e lu c i d a t i n g  n a tu r a l  h i s t o r y o f  ch r on ic  
h ep a t i t i s  B  and  m on i t o r in g  r es po ns e  to  i n t e r fe r on  o r  an t iv i ra l  t h e r ap y.  
S ur f ace  an t i gen  l eve l s  va r y b e t w een  d i f f e r en t  ph as es  o f  CH B p a t i en t s  
an d  a l s o  ac ro ss  d i f f e r en t  geno t yp es .   D ec l i ne  i n  su r f ace  an t i gen  l ev e l s  
d u r i n g  an d  a f t e r  i n t e r f e r on  th e r ap y h a s  go o d  p r ed i c t i v e  v a l u e  fo r  
r e s po ns e  to  i n t e r f e ro n  th e r ap y.  D ec l in e  o f  0 . 5  and  1 .0  l o g  s u r face  
an t i gen  l ev e l s  on  peg yl a t ed  in t e r f e ro n  th e r ap y p r ed i c t s  go o d  r es po n e  t o  
i n t e r fe r on  t he r ap y ( 1 3 ) .  H Bs A g s e ro c l ea r an ce  r ep r e sen t s  t h e  u l t im at e  
en dp o i n t  f o r  ch r on ic  H BV  in f ec t i o n  as  i t  i s  t ho u gh t  t o  r ep r e s en t  t h e  
co n t ro l  o f  H BV r ep l i c a t io n .   
 
N o n e th e l e s s ,  con t ro v e rs i e s  ex i s t  i n  t he  us e  o f  su r f ace  an t i gen  in  
c l i n i ca l  p r ac t i c e  and  i t  s t i l l  r em ai ns  a  r e s ea r ch  to o l  co nf in ed  to  few  
i ns t i t u t i on s .  T h er e  i s  p au c i t y o f  d a t a  on  t h e  us e  o f  s u r f ace  an t i gen  
q u an t i f i c a t i on  f rom In d i an  su b co n t i n en t  w he r e  mo s t  p a t i en t s  a r e  g iv en  
n u c l eos ( t ) i d e  i nh ib i to r s .  P r ed i c t i v e  v a l u e  o f  s u r face  an t i gen  
q u an t i f i c a t i on  fo r  r e s po ns e  to  n u c l eos ( t ) i d e  in h ib i to r s  i s  s t i l l  l o w  an d  












HBV DNA/Surface Antigen levels 
S e ro lo g i ca l  a s s a ys  f o r  s u r f ace  an t i gen  and  H BV D NA  m eas u r em en t s  
h av e  imp r ov ed  i n  re cen t  yea r s  d u e  to  t e ch no lo g i ca l  adv ances  w h i ch  
h av e  imm ens e l y co n t r ib u t ed  i n  un d e rs t and i n g  t h e  p a th o gen  t i c  
m echan i sms  o f  ch ro n i c  h epa t i t i s  b  i n fec t i on .  S ev e ra l  s tud i es  co nd uc t ed  
i nd ep en den t l y s h ow ed  co ns i s t en t  r es u l t s  b e t w een  H BV  DN A  an d  
s u r face  an t i gen  l eve l s  i n  d i f f e r en t  p h as e s  o f  ch r on ic  h ep a t i t i s  B  
p a t i en t s .  To  p u t  i n to  co n t ex t ,  H Bs A g p r o d u c t io n  p a th w a y an d  i t s  
r e l a t i on  wi t h  H BV D N A  an d  i n t r a -h epa t i c  c cc  DN A  n eed s  to  b e  
d e t e r min ed .  Th e r e  a r e  t h r ee  pa th w ays  f o r  t he  p r od u c t i on  o f  H BsA g  a s  
d ep i c t ed  in  F i gu r e  1 .  
  
 
D an e  p a r t i c l e  i s  t he  i n f ec t i ou s ,  en v e lo p ed  fo rm  o f  H Bs Ag.  H Bs A g  a l s o  
h a s  no n - in f ec t io us  f o rm s  w hi ch  a r e  f i l am en to us  o r  s ph e r i ca l .  Th es e  n on  
i n fec t io us  fo rm s  a re  p ro du ced  i n  ex ces s  t o  t h e  d an e  p ar t i c l e .  S u r f ace  
an t i gen  ( qH Bs A g)  co r r e l a t e d  wi th  c c c  D N A i n  m an y s tu d i e s  
( 1 0 , 11 ,1 6 , 17 ) . ccc  D N A  es t im at i on  r eq u i r es  co mpl ex  t e ch n i qu es  fo r  
e s t im at io n ,  t h ou gh  i t  i s  mo s t  a ccu r a t e  r e f l e c to r  o f  i n f ec t ed  hep a t oc yt e s .  
M o r eo v er  i t  r eq u i r es  l i v e r  b io ps y s p ec im en  ana l ys i s  fo r  c cc  D N A 
es t im at io n ,  t h e r e fo r e  i t  h as  b een  u s ed  o n l y i n  r e s ea r ch  s e t t i n gs .  
 
H BV  D NA  q u an t i f i c a t i on  b y P CR i s  r eq u i r ed  i n  d i agno s t i c  ev a lu a t io n  
o f  a l l  ch ro n i c  h epa t i t i s  B  p a t i en t s .  S e r u m H BV D NA  d ec l in e  r e f l e c t s  
d ec r eas e  in  v i ra l  r ep l i c a t i on  wh e r eas  su r f ace  an t i gen  d ec l i n e  r e f l e c t s  
r ed u c t i on  in  t r an s l a t io n  o f  m  R NA  p r od u ced  f r om  t r an sc r ip t i on a l l y 
a c t i v e  ccc  D N A or  i n t eg r a t ed  s eq u en ces .  Th us ,  su r f ace  an t i gen  
q u an t i f i c a t i on  p r ov i d es  com pl em en t a ry  i n f o rm at io n  wh i ch  m a y a i d  in  






HBsAg / HBV DNA Levels-Phases of CHB 
P r ev io us  c r os s - s ec t i on a l  s tu d i es  t ha t  co mp a r ed  H Bs A g and  H BV D NA  
l ev e l s  d u r in g  v a r iou s  ph as es  o f  ch ro n ic  H BV  in f ec t i o n  r ev ea l ed  
en cou r ag in g  s im i l a r  a c ro ss  d i f f e r en t  po p u l a t i on s  and  geno t yp es .  
A l t ho u gh  l ev e l s  a r e  v a r i ab l e  du r i n g  d i f f e r en t  p h as es  o f  ch r o n i c  
h ep a t i t i s  B ,  h i gh es t  l ev e l s  a r e  ob s e r v ed  i n  i n i t i a l  imm u not o l e r an t  ( IT )  
p h as e  w h e r e  a l an ine  amin o t r an s fe r a ses ( A LT )  l ev e l s  a r e  no r ma l  wi th  
n o / min im al  i n f l amm at io n  on  l i v e r  b iop s y.  HBsAg levels declined in 
immune clearance( IC) phase and therafter it  progressively decline in patients 
who achieved e antigen seroconversion with normal ALT l evels ( 1 8 ) .  Lo w es t  
l ev e l s  o f  s u r f ace  an t i gen  a r e  o bs e rv ed  in  i nac t iv e  ca r r i e r  p h as e  w hi ch  
a l so  i s  ch a r ac t e r i s ed  b y h i gh es t  H BsAg/ H BV  DN A  r a t io  (1 4 ,  18 ,  19 ) .   
 
C h an  e t  a l  fo l lo w ed  6 8  hep a t i t i s  E  Ant i gen  n ega t i ve  ch r on i c  h ep a t i t i s  B  
p a t i en t s  and  s ho w ed  t h a t  d ec l i n e  t r ends  o f  s u r f ace  an t i gen  ( >  1  lo g 1 0  
IU / ml   d ec l i n e  b e tw een  in i t i a l  an d  l as t  v i s i t s )  r e f l e c t s  be t t e r  i m mu ne  
co n t ro l  ov e r  CH B in f ec t io n ,  a s  ob j ec t iv e l y a s s e s s ed  b y  h i gh e r  s e ro -
c l ea r an ce  r a t e s  and  s t r on ge r  D N A su pp r e s s i on  (1 8) .  B r une t t o  e t  a l  
s tu d i ed  2 09  geno t yp e  D p a t i en t s  an d  co n c l ud ed  t h a t  su r f ace  an t i gen  
l ev e l s  a r e  l ow er  i n  i n ac t i v e  ca r r i e r s  t han  ac t i v e  ca r r i e r s  (2 0 ) .  S e t o  e t  a l  
f r om  Ho n g  K on g  s tu d i ed  20 3  t r e a t m en t  n a i v e  e  an t i gen  nega t iv e  C H B 
p a t i en t s  ( gen o t yp e  B  an d  C )  w ho  ach i ev ed  s e ro c l ea r an c e .  In  t h i s  s tu d y 
o p t im al  cu t  o f f  t o  p r ed i c t  H BsA G s e roc l ea r an ce  wi th in  3  yea r s  o f  
f o l lo w  u p  w e re  <  20 0  IU / ml ( s ens i t i v i ty  8 4 . 2 %; sp ec i f i c i t y  7 3 . 4  % )  and  
0 . 5  l o g  r ed uc t io n  IU /m l / yea r  ( s en s i t i v i t y , 6 2 . 8  % and  s p ec i f i c i t y , 8 8 . 7  
% )  (2 1 ) .   
 
 

























1. Abbreviation: anti-HBe, antibody to hepatitis B e antigen. 
HBsAg level 
(log10IU/mL) 
5.0 3.0-4.0 1.5-2.2 2.5-3.0 18 
4.5 4.0 2.9 3.4        19 
5.0 4.4 3.1 4.0 14 
HBV DNA level 
(log10IU/mL) 
7.5-8.5 6.0-7.0 1.0-2.4 3.9-4.6 18 
8.2 8.0 <2.6 5.0 19 
8.0 7.5 2.5 5.5 14 
HBsAg/HBV 
DNA ratio (log 
IU/mL) 
0.6-0.8 0.5-0.7 0.7 0.6-1.0 18 
0.5 0.5 1.0 0.6 19 
0.6 0.6 1.2 0.7 14 










T w o r ecen t  s tu d i es  f r om  As i a  fo l lo w ed  u p  39 0  an d  10 3  e  an t i gen  
n ega t i v e  C H B p a t i en t s  r e sp ec t iv e l y,  and  fo un d  H BsA g l eve l  o f  <  1 00  
IU / ml  p r ed i c t i v e  o f  ev en tu a l  H Bs A g s e r o c l ea r an ce  (2 3 ,  2 4 ) .  Op t im al  
cu t  o f f  v a l u e  o f  H BV  D NA  t o  d e f in e  inac t i v e  ca r r i e r  i s  s t i l l  deb a t ed .  In  
co mp a r i so n  t o  i n a c t iv e  ca r r i e r s  e  an t igen  n ega t iv e  h epa t i t i s  ( E NH )  
p a t i en t s  h av e  h i gh er  D NA  an d  su r f ace  an t i gen  l ev e l s  (1 4 ,1 8 ,1 9 , 20 ) .  
A l t ho u gh  ex ac t  v a lu e s  d i f f e r ,  su r f ace  an t i gen  l ev e l s  o f  1  t o  2  x  10
3
 
IU / ml  an d  H BV D NA  lev e l s  o f  2  X  10
3
 IU / m l  h av e  a  d i agn os t i c  
a ccu r acy ( 9 4  t o  100  % )  fo r  i nac t iv e  ca r r i e r s .  Ho w ev e r  mo s t  s t ud i es  a r e  
r e t ro sp ec t iv e  and  req u i r e  v a l i d a t i on  p r o sp ec t iv e l y i n  p a t i en t s  i n f ec t ed  
w i t h  a l l  gen o t yp es .  Fu r t h e r  s tu d i es  m ay co n f i rm  th e  u t i l i t y  o f  s u r f ace  
an t i gen  in  c l i n i ca l  m an agem ent  o f  C HB p a t i en t s  b ecau s e  t h ey can  b e  
u s ed  t o  d e f in e  mo re  c l ea r l y w h o  r equ i r e s  t r ea tm en t  and  wh o  d o  no t .  
T h ey m a y a l s o  reduce  th e  n eed  fo r  l i v e r  b i op s y i n  p a t i en t s  w i th  mi ld  
e l eva t i on  o f  l i v e r  enz ym es  an d  lo w l eve l s  o f  s u r f ace  an t i gen  an d  D NA  








qHBsAg trends  during antiviral  therapy  
Entecavir (ETV) 
Lee  e t  a l  f ro m Ko rea  s tu d i ed  k in e t i cs  o f  q H BsA g in  9 5  CH B p a t i en t s  on  
en t ecav i r  ( ET V  0 .5  m g  o d )  t h e rap y f o r  t wo  yea r s  ( 27 ) .  Mo s t  p a t i en t s  
w e r e  H BeA g +  (6 0% )  wh o  w e r e  i n f ec t ed  wi t h  gen o t yp e  C   .  Base l in e  
A LT  ( p =0 .0 13 ) ,  H BV  D NA  (p =0 . 04 0)  an d  q H Bs A g l ev e l s  (p =0 . 03 3 )  
w e r e  p r ed i c to r s  o f  V R  ( v i ro lo g i ca l  r e sp o ns e )  i n  H BeA g +  p a t i en t s .  T h e  
h i gh es t  p r ed i c t i v e  v a lu e  o f  VR  was  wi t h  b as e l in e  q  H Bs Ag w i t h  th e  
a r ea  u nd e r  t h e  cu r ve  o f  0 . 82 3  ( P  <  0 .00 1 ) .  T h e  h i gh es t  p red i c t i v e  va lu e  
w as  o b t a i ned  a t  a  cu t  o f f  v a lu e  o f  3 . 98  IU / m L  w i t h  a  s ens i t i v i t y  o f  
8 6 .8 % and  a  sp ec i f i c i t y  o f  7 8 . 9% . S e ro l o g ica l  r es po n e  (SR )  w hi ch  w as  
d e f i nd  as  H BeA g los s  a t  24  mo nt hs  o f  t h e r ap y .  In  t h i s  su bgr o u p  o f  
p a t i en t s  r edu c t io n  in  qH BeA g w as  mo re  p ro f ou nd  in  p a t i en t  w ho  
ach iev ed  SR  ( SR + ) .  C o r r e l a t io n  b e t w een  q H BsA g and  H BV  D NA  w as  
m os t  p r o fo un d  i n  E  an t i gen  p os i t i v e  pa t i en t s  an d  p eak ed  a f t e r  6  m on th s  
o f  E T V th e r ap y.  
Fo l l ow in g  con c l us io ns  can  b e  m ad e  d ur i n g  th i s  s t ud y.  
1 .  Bo th  q uan t i t a t i ve  su r f ace  an t i gen  ( q H Bs A g )  and  q u an t i t a t i ve  E  
an t i gen  d ecr ea s ed  m ark ed l y w i t h  th e rap y.   
2 .  V i r o l o gi ca l  an d  S e ro lo g i ca l  r e sp ons e s  w e r e  p r ed i c t ed  b y b a s e l in e  
q H Bs A g l ev e l s  and  o n  t r e a tm en t  d ec l in e  i n  qH BeA g l ev e l s  i n  H BeA g+  
p os i t i v e  p a t i en t s  r es p ec t i v e l y.  
Fu n g  e t  a l  a l s o  s tud i ed  p a t t e r ns  o f  s u r f ace  an t i gen  k i n e t i c s  o n  en t ecav i r  
t h e r ap y f o r  t wo  yea r s  (2 8 ) . Amo n g  1 66  C H B p a t i en t s  r e c ru i t ed  in  t h i s  
s tu d y,  6 8  p a t i en t s  (4 1 % )  w e re  e  an t i gen  pos i t i v e .  A t  b as e l i n e ,  q H BsA g 
l ev e l s  co r r e l a t ed  wi th  ag e ,  H BV DN A  an d  A LT  l ev e l s  ( r  =  −  0 .4 29 ,  
0 . 60 7 ,  and  0 .2 54 ,  r e s p ec t i v e l y,  P  <  0 .0 5 )  i n  a l l  p a t i en t s .E T V th e r ap y  
l e ad  t o  r edu ced  co r r e l a t i on  b e tw een  HBV  D N A an d  q H BsA g l ev e l s  and  
i t  w as  lo s t  a f t e r  2  yea r s  o f  t h e r ap y.  T h e r e  w as  an  ov e r a l l  d ec l i n e  in  
H Bs A g l ev e l s  f r om b as e l in e  to  yea r  1  t o  yea r  2  (3 ,3 77 .4  v s .  2 ,3 16 .5  v s .  
1 , 90 3 . 0  IU  /  ml ,  r e s p ec t i v e l y,  P  <  0 .00 1 ) . 14  p a t i en t s  h ave  s i gn i f i c an t  
i n c r ea s e ,  5 0  pa t i en t s  h ad  s i gn i f i can t  dec l i n e  and  1 02  p a t i en t s  h ad  no  
s i gn i f i c an t  chan ges  a f t e r  2  yea r s  o f  ET V  t he r ap y . 2 5  p a t i en t s  ( 37 % )  h ad  
E  an t i gen  s e ro co nve r s i on  an d  15 1  p a t i en t s  ( 91 % )  h ad  H BV  D NA  
s up p r es s io n  a f t e r  24  w eeks  o f  E T V t he r ap y .  Bas e l in e  q HBs A g o r  e a r l y 
d ec l in e  i n  qH Bs A g l ev e l  a t  w eeks  1 2 / 24  w er e  n o t  p r ed ic to r s  o f  H BeA g 
s e r o co nv e rs i on  a t  24  w eeks .   
 
C on c l us io ns  d e r i ved  f rom  t h i s  s tu d y w e r e  
1 .  E TV  t h er ap y l e ad  t o  p ro fo un d  d ec l in e  i n  H BV D N A l ev e l s  w i th  n o  
s i gn i f i c an t  d ec l i ne  i n  q H Bs A g l eve l s .  
2 .  T he r e  w as  no  co r r e l a t i on  b e t w een  q  H Bs A g d ec l i n e  a t  w eek  1 2 /2 4  
w i t h  H BV D N A su pp r e s s i on  o r  E  an t i gen  s e r ocon v e rs i on .  
 
T h ou gh  th e r e  w e r e  s om e  l im i t a t io ns  no t ed  in  t h i s  s tu d y .  F i r s t l y ,  
p a t i en t s  w e r e  f o l l ow ed  u p  fo r  o n l y s ho r t  sp an  o f  t i me .  Seco nd l y,  n o ne  
o f  t he  pa t i en t  h ad  H Bs A g se r o c l ea r ance  so  p r ed i c to r s  o f  r e s po ns e  to  
H Bs A g se r o c l ea r ance  cou l d  no t  b e  ca l cu l a t ed .  Th i r d l y,  gen o t yp i c  
an a l ys i s ,  c cc  D N A e s t im at io n  and  r e s i s t an t  m ut a t i on a l  ana l ys i s  w e r e  
n o t  d on e .  
 
J un g  e t  a l  f r om  K o rea  s tu d i ed  28  C H B p a t i en t s  w ho  we r e  E  an t i gen  
p os i t i v e  on  E T V t he r ap y ( 2 9 ) .  q H BsAg l ev e l  sh o wed  a  mean  o f  4 .0 ,  3 . 7 ,  
a n d  3 . 6  l o g1 0 IU / mL a t  b a se l i ne ,  6 ,  and  12  mo nt hs ,  r es p ec t i v e l y. H BV  
D N A  l ev e l s  sh o wed  a  m ean  o f  8 .1 ,  3 . 1 ,  and  2 .4  l o g10  co p ie s /m L a t  
b a s e l i n e ,  6 ,  and  1 2  m on th s ,  r e sp ec t i v e ly .  D ec l in e  in  q  H Bs A g and  H BV  
D N A  w er e  s i gn i f i can t  (P <0 . 00 1) . Af t e r  12  m ont hs  o f  t h e rap y,  t h e r e  was  
co r r e l a t i o n  no t ed  be t w een  H BV  DN A  lev e l s  and  q H BsA g l ev e l s .  
( g=0 . 39 1 ,  P =0 .0 44 ) . H Bs A g r es po ns e  was  n o t ed  i n  f i v e  p a t i en t s  an d  
cu mul a t iv e  i n c id ence  o f  H BeA g lo s s  w as  n o t ed  i n  80 %  as  co mp a r ed  to  
3 0  %  i n  t ho s e  wi tho u t  H BeA g lo s s (p =0 . 03 4) .  Th i s  s t ud y s ho w ed  t h a t  
d ec l in e  i n  s u r face  an t i gen  l ev e l  co r r e l a t ed  wi t h  H BV  D NA  on  en t ecav i r  
t h e r ap y an d  s i gn i f i c an t  dec l in e  i n  su r face  an t i gen  a t  1  ye a r  m a y b e  
p r ed i c t o r  o f  an t iv i ra l  r e sp on s e ,  p a r t i cu l a r l y H BeA g s e r oco nv e r s io n .  No  
gen o t yp i c  an a l ys i s  w as  d on e  in  t h i s  s tu d y b u t  r esu l t s  m ay b e  ap p l i c ab l e  





H Bs A g se r o c l ea r ance  w as  n o t ed  a f t e r  t eno fo v i r  t h e r ap y i n  e  an t i gen  
p os i t i v e  p a t i en t s  on l y  ( 3 0 ) . Af t e r  1 ,2  an d  3  yea r s  o f  t enof o v i r  t h e r ap y,  
s e r o c l ea r an ce  r a t es  o f  3 %, 6%  an d  8 % w er e  n o t ed .  G an e  e t  a l  s t ud i ed  
1 7 6  H BeA g +  C H B p a t i en t s  o n  t eno f ov i r  ( 30 ) .  H e  ob s er v ed  m ed i an  
b a s e l i n e  qH Bs A g l ev e l  4 . 56  l o g1 0 IU / m L.  T h e  m ed i an  qHBs A g ch an ge  
f r om  b as e l i n e  i n  t h i s  s tu d y  a t  W1 44  was  -0 .6 3 lo g1 0 IU / mL.  H Bs A g lo s s  
w as  n o t ed  i n  8  % o f  H BeA g p os i t i v e  pa t i en t s  i n  e ach  g r ou p . In  th i s  
s tu d y,  6 %  an d  7 % se r o con ve r t ed  to  an t i - H Bs  b y W 14 4  ( TD F - T D F  and  
A D V - TD F gr ou ps ,  r e s p ec t iv e l y) . P r ed ic t o r s  o f  H BsA g lo s s  n o t ed  i n  t h i s  
s tu d y w e r e :  h i gh er  b a s e l i n e  qH Bs A g  l ev e l ( OR =  4 8 . 8 ) ,  h igh e r  b as e l i n e  
n ec r o - in f l am m ato ry  s co r e ( OR =1 . 7 )  and  pa t i en t s  w i th  Geno t yp e  D / A (O R 










Wu r s th o rn  e t  a l  s tud i ed  1 62  H BeA g +  C H B p a t i en t s  on  t e l b i vu d in e  
t h e r ap y f o r  t h r ee  yea r s  ( 31 ) .q H Bs A g l ev e l s  and  i t s  co r r e l a t i on  wi t h  
H BV  D NA  was  s t ud i ed .  qH Bs A g l ev e l s  (m ean  ±  S D)  r ed uced  f r om  
b as e l i n e  (3 .8  ±  0 .6  l o g 1 0 IU / m L)  t o  t r e a t men t  w eek  24  (3 .4  ±  0 . 7  
l o g 1 0  IU / m L) ,  t r e a tm en t  yea r  1  (3 .3  ±  0 . 8  l o g 1 0  IU / m L) ,  an d  t r e a tm en t  
yea r  3  ( 3 . 0  ±  1 . 4  l og 1 0  IU / m L)  ( P  <0 . 00 0 1) . H Bs A g s e r oc l ea r an ce  w as  
n o t ed  i n  6 % a f t e r  t h r ee  yea r s  o f  t h e r ap y . 8  o f  32  p a t i en t s  w i t h  r ap id  
H Bs A g dec l in e  v e r s us  n on e  o f  5 6  pa t i en t s  w i th  s t ead y H Bs A g l ev e l s  
a ch iev ed  H Bs A g l os s  a t  yea r  3  ( P  =  0 .0 0 24 ) . F a s t es t  d ec l in e  o f  s u r f ace  
an t i gen  w as  n o t i c ed  i n  gen o t yp e  A  p a t i en t s ,  im p l yi n g  gen o t yp i c  
an a l ys i s  a s  a  d e t e rm in an t  o f  s u r face  an t i gen  d ec l i n e .  Li ve r  b io ps y 
p e r f o r med  a f t e r  1  yea r  i n  t h os e  w ho  ach i ev ed  se r o -c l ea r ance  r ev ea l ed  
ab s en ce  o f  v i r a l  an t i gen s .  I t  c an  b e  con c lu d ed  f r om th i s  s t ud y t h a t  
e f f ec t iv e  s up pr e s s io n  o f  v i r a l  r ep l i c a t i on  as  m eas ur ed  b y  r ap id  qH Bs A g 
d ec l in e  o n  T DT  th er ap y  co u l d  p r ed i c t  H Bs A g se r o c l ea r ance  r a t e s .  
W ei  C a i  e t  a l  s tu d ied  1 7  H BeA g +  p a t i en t s  t r e a t ed  wi t h  T d T  fo r  t wo  
yea r s  ( 3 2 ) .  H Bs A g l ev e l s  <  2 lo g1 0  IU / m l  a t  2  yea r s  w e r e  h i gh l y 
p r ed i c t i v e  o f  su s t a in ed  v i r a l  r e sp on s e   a t  2  yea r s  o f f - t r e a tm en t (  P PV  o f  
9 3  %  an d  n e ga t iv e  p r ed i c t i v e  v a l ue ( NP V )  o f  1 00  % ) . In  th i s  s ub gr ou p  o f  
p a t i en t s  su r f ace  an t i gen  co ns i s t en t l y  d ec l i n ed  f r om  b as e l in e .  q H Bs A g 
d ec l in e  ra t es  o f  >  0 . 8  and  >  1  lo g  10  IU /m l  a t  6 mo nth  and  1  yea r  w e r e  
p r ed i c t i v e  o f  su s t a in ed  r e sp ons e  (PP V -7 5  % , NPV - 86 %  a t  w eek  2 4 ;  
PP V -7 5  %  and  NP V8 6 % a t  w eek  5 2) .  
 Interferon (IFN) therapy 
J ans s en  e t  a l  f i r s t  p r op os ed  i n  19 94  th a t  su r f ace  an t i gen  q uan t i f i c a t io n  
m a y b e  us e fu l  fo r  m on i to r i n g  i n t e r fe ro n  t r e a t ed  H BeA g p os i t i v e  
p a t i en t s  w h en  a  s i gn i f i c an t  d ec l in e  o ccu r r ed  i n  i n t e r f e r on  t r e a t ed  
p a t i en t s  w ho  h ad  HBeA g s e ro con v e rs io n  r e sp on d ed  to  t he r ap y b u t  n o t  
i n  p a t i en t s  wi t ho u t  H BeA g s e ro con ve r s i on ( p <0 .0 01 )  ( 33 ) .  T h us  H Bs A g 
q u an t i f i c a t i on  w as  p r op os ed  as  a  s im pl e  m et ho d  fo r  m on i t o r in g  th e r ap y 
i n  C H B p a t i en t s  b u t  l a ck  o f  com m er c ia l  a s s a ys  p r ec l ud ed  i t s  
w i desp r ead  u t i l i t y  u n t i l  r e cen t l y.  
M an es i s  e t  a l  an d  Wi gan d  e t  a l  p ro pos ed  th a t  q H BsA g mo ni to r i n g  co u ld  
p r ed i c t  H Bs A g s e ro - c l ea ran ce  a f t e r  5 . 4  yea r s  o f  S VR  t o  IF N  th e r ap y o r  
a f t e r  10 .6  yea r s  o f  l am iv ud in e  ( LA M )  t h e r ap y ( 3 4 ,  3 5 ) .  Su bs equ e n t l y 
s ev e ra l  o th e r  s t ud ie s  h av e  c l ea r l y d em on s t r a t ed  t h a t  H Bs A G d ec l i n e  i s  
m o re  p r omi n en t  and  r ap i d  w i th  IFN  t he r ap y t h an  wi t h  nuc l eos ( t ) i d e  
an a lo gu es ( 30 ,3 1 , 36 - 4 1 ) . I t  co u ld  b e  d ed u ced  t ha t  qH Bs A g d ec l i n e  i s  






Predict ing Response to IFN therapy .  
S i n ce  r es po ns e  r a t e  o f  p eg yl a t ed  i n t e r fe r o n  t h e r ap y i n  H BeA g +  an d  
H BeA g –  p a t i en t s  i s  3 0  %  an d  20  %  r es p ec t i v e l y,  i t  i s  imp o r t an t  t o  
d e r i v e  m ar k e rs  p r ed i c t i n g  t r e a tm en t  su cce ss  b o th  fo r  p a t i en t  and  
p h ys i c i an .  C h an  HL s h o w ed  t h a t  h i ghe r  r es po ns e  to  IFN  t h er ap y i n  
H BeA g +  p a t i en t s  w h os e  b as e l in e  q HBs A g l ev e l s  w e re   <1 0  00 0  IU / m l  
( 4 2 ) .  T ho u gh  th i s  r e s u l t  w as  no t  v a l i da t ed  i n  o t h e r  s tu d i es ,  s i gn i f i c an t  
o n  t r e a tm en t  l ev e l s  co r re l a t ed  w i t h  s us t a in ed  r es po ns e  t o  i n t e r f e ro n  
t h e r ap y.  2 0 2  e  an t igen  po s i t i v e  p a t i en t s  i n  E ur op e  we r e  s t ud ied  b y 
S on n ev e l d  e t  a l ,w ho  w er e  t r e a t ed  wi t h  IFN  f o r  52  weeks .  q H Bs A g 
d ec l in e  a t  w eek  5 2 (3 . 3  ve r su s  0 . 7  l o g  1 0  IU / ml )  and  w eek  78 (3 .4  v e r s us  
0 . 35  lo g  10  IU / ml )  p r ed i c t ed  s us t a in ed  r e sp on se  (3 7 )   
T r ea t m en t  wi t h  P EG - IFN  a l p h a  2b  w i th  o r  wi t ho u t  l ami vu d i n e  ( LA M )  i n  
9 2  E  an t i gen  p os i t i v e  p a t i en t s  f r om Ho n g  Ko n g  fo r  32  t o  4 8  w eeks  w as  
s tu d i ed  b y C h an  e t  a l .  Th e y d emo ns t r a t ed  qH Bs A g l ev e l  <  1 50 0  IU / ml  
a t  w eek  12  an d  qHBs A g l ev e l s  <  3 00  IU  / ml  a t  w eek  2 4  co u l d  p red i c t  a  
S VR  1 2  m on th s  a f t e r  t r e a t m en t  (4 2 ) .  
 
 P i r a tv i s u th  e t  a l  a l s o  d em on s t r a t ed  tha t  q H BsA g l ev e l  <15 0 0  IU  / ml  a t  
m on th  3  o f  i n t e r f e ro n  th e r ap y w as  as so c i a t ed  w i t h  H BeAg co nv e r s io n  
r a t e  o f  57  %  a t  6  mo n t hs  a f t e r  t r e a tm en t .  Amo n g  p a t i en t s  w ho  
s e r o co nv e r t ed  1 8  % h ad  H Bs A g s e r oc l ea r an ce (4 4) .  
In  H BeA g-  p a t i en t s ,  s t u d i es  h av e  d emo ns t ra t ed  th a t  ba s e l i n e  su r f ace  
an t i gen  l ev e l s  do  no t  p red i c t  r es po ns e  to  p eg - IFN  t h e r apy b u t  s us t a in ed  
r e s po nd e rs  h av e  m ar k  d ec r eas e  in  s u r face  an t i gen  l ev e l s  a t  w eek  48  
( 2 .1  +   1 .2  l o g  1 0  IU /m l )  .  B ru n e t t o  e t  a l  sh ow ed  th a t  b o th  qH Bs A g 
l ev e l  <10  IU  /m ( 12%  o f  p a t i en t s ) l  a t  en d  o f  t r e a t m en t  an d  >1 . 2  lo g  10  
IU / ml  d ec l in e  d u r in g  th e r ap y w e r e  a s s o c i a t ed  wi t h  su r f ace  an t i gen  
c l ea r an ce  3  yea r s  a f t e r  t h e r ap y ( RR  o f  2 2 . 8  an d  10 .8  r es pec t i v e l y,  p  <  
0 . 00 01 )  ( 40 ) . Mo u ca r i  e t  a l  s ho w ed  s im i l a r  r es u l t s  wi t h  0 . 5  an d  1  lo g  
d ec l in e  i n  qH Bs A g  l ev e l s  a t  w eek  12 (1 9 % o f  p a t i en t s )  and  24 (2 3  %  o f  
p a t i en t s )  o f  P E G - IFN  a lp ha  2 a ,h ad  goo d  p r ed ic t iv e  v a lu e  f o r  sus t a in ed  
r e s po ns e (  89  % a t  m on th  3  an d  9 2 % a t  m on t h  6  )  (4 5 ) .  Mar ce l l i n  e t  a l  
s tu d i ed  1 20  e  an t i gen  n ega t i v e  p a t i en t s  an d  sh ow ed  th a t  d ec l in e  o f  >  
1 0 % a t  12  w eek  o f  i n t e r fe r on  t he r ap y w as  a s s o c i a t ed  wi th  a  1  yea r  o f f  
t h e r ap y S V R o f  47  %  and  s e ro c l ea r an ce  r a t e  o f  2 3  % a t  5  yea r s  a f t e r  
t h e r ap y ( 4 1 ) .  H BV  D N A  d ec l in es  t h r ou gh o u t  t h e  t r e a tm en t  and  th e r e  
w as  n o  d i f f e r ence  be t w een  r e sp on d e rs  an d  r e l aps e r s .  
S u r f ace  an t i gen  l eve l s  p r ed i c t in g  r es po ns e  t o  i n t e r f e r on  th e r ap y w e r e  
n o t i c ed  ac ro ss  a l l  gen o t yp es  (4 6 ) .  A l tho u gh  th e s e  l o w s u r f ace  an t i gen  
l ev e l s ,  p red i c t in g  re s po ns e  to  t h e r ap y w e r e  ach i ev ed  in  l e s s  t h an  25  %  
o f  p a t i en t s ,  i t  c an  m ot i v a t e  o r  en co urage  i n t e r f e r on  t r ea t ed  p a t i en t s  t o  
co mpl e t e  t h e rap y.    
 
 
Predict ing  Non-Response 
S ur f ace  an t i gen  q uan t i f i c a t i on  m a y p red i c t  no n - r e sp on s e  t o  t h e r ap y an d  
i d en t i f y p a t i en t s  wh o  n eed  ea r l y d i s con t i nu a t io n  o f  t h e r ap y o r  
a l t e r n a t i v e  t r e a tm en t  r eg im es .  Bo t h  e  an t i gen  po s i t i v e  o r  n ega t i v e  
p a t i en t s  h av e  d emon s t r a t ed  h i gh  n ega t i v e  p r ed i c t iv e  v a l ue  ( NP V )  fo r  
r e s po ns e .  S on nev e ld  e t  a l  d em ons t ra t ed  NP V of  9 7  %  i n  20 2  e  an t i gen  
p os i t i v e  p a t i en t s  (74  % w er e  gen o t yp e  A  o r  D )  on  in t e r f e ro n  th e r ap y 
b a s ed  o n  an y d ec l in e  i n  su r f ace  an t i gen  l eve l s  a t  w eek  12  
( 3 7 ) .P i r a tv i su th  e t  a l  r epo r t ed  82  % NP V f o r  r es po ns e  in  e  an t i gen  
p os i t i v e  gen o t yp e  B / C  i n f ec t ed  p a t i en t s  h av i n g  s u r f ace  an t i gen  d ec l i n e  
a t  w eek  12  (4 4) .C han H L e t  a l  f r om H on g  K on g  r ep o r t ed  N P V of  8 6  %  
f o r  s u r f ace  an t i gen  l ev e l s  <  1 50 0  a t  12  w eeks  an d  89  % fo r  s u r f ace  
an t i gen  l ev e l s  <  3 00  a t  2 4  w eek s  i n  e  an t i gen  po s i t i v e  p a t i en t s  (4 2 ) .  
A n o t he r  Ch in e se  s tu d y o f  e  an t i gen  p os i t i v e  i n f ec t ed  p a t i en t s  s ho w ed  
t h a t  su r f ace  an t i gen  l ev e l s  <  15 00  a t  3  m on th s  an d  <  2 840  a t  6  mo n t hs  
h ad  NP V o f  91  % an d  9 5  % r es p ec t i v e l y f o r  r es po ns e .  For  e  an t i gen  
n ega t i v e  p a t i en t s  M ou ca r i  e t  a l  r ep o r t ed  a  NP V  o f  90 %  fo r  >  0 . 5  l o g  
d ec l in e  a t  w eek  1 2  an d  97 %  fo r  >  1  l og  d ec l in e  a t  w eek  24  i n  a  s t ud y 
p o pu l a t io n  in vo l v in g  a l l  gen o t yp es  (45 ) .  R i j ck bo r s t  e t  a l  s t ud ied  
gen o t yp e  D  e  an t i gen  n ega t i v e  p a t i en t s  an d  d em ons t ra t ed  NP V  o f  10 0  %  
b as ed  o n  comb in a t io n  o f  d ec l i n e  i n  su r f ace  an t i gen  l ev e l  an d  >  2  l o g10  
IU  / ml  d ec l i n e  i n  HBV  D N A l ev e l s  f r om  b ase l i ne  t o  w eek  1 2  (4 7 ) . Th i s  
r e s u l t  w as  v a l i d a t ed  i n  ano t h e r  coh or t  o f  p a t i en t s  s o  s t opp in g  r u l e  f o r  
i n t e r fe r on  t he r ap y can  b e  ap p l i ed  wi t h  1 00  %  NPV .  Th i s  c an  h e l p  in  
p a t i en t  m an agem ent  an d  encou r age  pa t i en t s  t o  con s id e r  i n t e r f e r on  
t h e r ap y a s  f i r s t  l i ne  t r e a tm en t .  T h i s  i s  p a r t i cu l a r  app l i cab l e  i n  e  


















Special  Populat ions  
1 .  HBV/HCV coinfection  
S ur f ace  an t i gen  k ine t i c s  w as  d on e  i n  HBV / HC V co - in f ec t ed  pa t i en t s  
w h o  w e r e  t r e a t ed  wi th  IN F  an d  R ib av i r i n  fo r  H CV  i n f ec t io n .  
In t e r e s t i n gl y,  5 0  % su r f ace  an t i gen  d ec l i n e  a t  w eek  1 2  i n  p a t i en t s  wh o  
h ad  un d e t ec t ab l e  HBV  D N A a t  b a se l i ne  h ad  redu ced  l i k e l i ho od  o f  H BV  
D N A  r eac t iv a t io n  (PP V -8 9 . 5  % )  ( 48 ) . In  t h i s  s tu d y l o w  s u r f ace  an t i gen  
l ev e l s  we r e  a s s o c i a t ed  wi t h  H Bs A g s roc l ea r an ce  ( 40 %  f o r  b a s e l i n e  
H Bs A g l ev e l s  <  20  IU / m L an d  2 % f o r  l ev e l s  > 12 0  IU / m L,  P  <  
0 . 05 ) . Th i s  s t ud y r a i s es  t h e  p os s ib i l i t y  t h a t  i d en t i f i c a t i on  o f  t ho se  
p a t i en t s  w ho  a r e  a t  r i s k  o f  r eac t iv a t ion  an d  n eed s  N A t h er ap y m a y b e  
p os s i b l e .  
2.  HBV/HIV coinfection  
Zo u t en d i j k  e t  a l  s tu d i ed  10 4  H IV / H BV  in f ec t ed  p a t i en t s  ( p r ed omi nan t l y 
gen o t yp e  A )  i n  N e th e r l and s  w ho  w e r e  t r e a t ed  wi t h  t en of ov i r  a s  p a r t  o f  
H A AR T th e r ap y an d  s ho w ed  t h a t  e a r l y  d ec l i n e  o f  s u r face  an t i gen  
w i t h i n  1  yea r  co r r e l a t ed  wi th  im p ro ved  C D 4  cou n t s  an d  H Bs A G 
s e r o c l ea r an ce  i n  e  an t i gen  po s i t i v e  p a t i en t s  (4 9 ) .  T h i s  exp l a in s  t h e  
i mp or t an ce  o f  i mmu n e  r e s to r a t io n  b y H A AR T in  H IV / H BV  co - in f ec t ed  
p a t i en t s .  A  s i gn i f i can t  d ec l i ne  i n  H BsA g l ev e l  o f  2 .2 lo g  IU / m L a t  yea r  
6  w as  n o t ed  w i t h in  t h e  H BeA g - pos i t i ve  po pu l a t i on ,  wh i l e  a  mi n i ma l  
d ec l in e  w as  ob s er ved  i n  H BeA g - nega t i v e  p a t i en t s . A d ec l in e  in  H Bs A g 
o f  a t  l e as t  2 lo g  IU / m L a t  24  w eeks  w as  h i gh l y p r ed i c t i v e  o f  H Bs A g 
s e r o c l ea r an ce .   
Perspectives 
T h e r e  i s  s t i l l  mo r e  t o  l e a r n  abo u t  d ec l in e  o f  s u r f ace  an t i gen  k in e t i cs  on  
t h e r ap y.  P r ed i c t i on  o f  s e r o c l ea r an ce / se r o con ve r s i on  b y su r f ace  an t i gen  
q u an t i f i c a t i on  n eeds  fu r t h e r  co n f i rm at i on .  M ajo r i t y  s t u d ie s  a re  d on e  i n  
E u ro p e  and  A s i a  and  w e  m a y n eed  s t ud i e s  i n  d i f f e r en t  p a r t s  o f  wo r l d  to  
s ho w  i t s  u t i l i t y  a c r o ss  a l l  geno t yp es .  P r ed ic t i on  mo d e l s  u s i n g  H BV  
D N A ,  A LT  and  s u r f ace  an t i gen  n eed s  t o  b e  d e t e rmi n ed .  N ev e r t he l es s ,  
w i t h  su r f ace  an t i gen  qu an t i f i c a t i on  w e  m ay b e  ab l e  t o  i nd i v i du a l i s e  






























 Primary Objective  
T o  s t ud y t h e  p a t t e rn  o f  d ec l in e  in  Hepa t i t i s  B  s u r f ace  an t i gen  l ev e l s  
( q H BsA g)  on  an t i -v i ra l  t h e r ap y  ( b o t h  n u c l eos ( t ) i d e  an d  in t e r f e ro n  
t h e r ap y)  an d  i t s  co r r e l a t i on  w i t h  dec l in e  i n  H BV D N A l ev e l s .  
 
Secondary Objectives  
1 .  St ud y t h e  p r ed ic to r s  o f  v i r o l o gi ca l  r esp o ns e .  
2 .  St ud y t h e  co r re l a t i o n  o f  q H Bs A g  d ec l i n e  wi t h  e  an t i gen  s t a tu s ,  














                     







 Study Population 
T hi s  i s  a  p r os p ec t iv e  s tu d y w h i ch  w as  con du c ted  in  d ep ar t men t  o f  
H ep a t o l o g y a t  Ch r i s t i an  M ed i ca l  Co l l ege ,  V e l lo r e  f ro m J an  20 11  to  
D ecemb er  20 12 .P a t i en t s  wi t h  ch r on i c  h ep a t i t i s  B(C H B)  w h o  w e r e  
s t a r t ed  o n  an t i v i r a l  t h e r ap y d u r i n g  t h i s  p e r i od  w er e  i nc lud ed  in  t h e  
s tu d y.  A n t i v i r a l  t he r ap y ( n u c l eo s ( t ) i de  o r  i n t e r f e r on )  was  s t a r t ed  
acco rd in g  to  c l i n i c i an ’ s  d i s c r e t i on .  T he  p ro t o co l  fo l l ow ed  w as :  
a .  e  an t i gen  p os i t i ve  ( H BeA g +v e )  p a t i en t s  w i th  DN A  lo ad s  >20  0 00  
IU / ml   i r r e sp ec t i v e  o f  A LT  l ev e l s  
b .  e  an t i gen  n ega t iv e  (H BeA g –v e )  wi t h  D NA  l o ad s  >  200 0  IU / ml   an d  
e l eva t ed  A LT  l ev e l s  
c .  H BeA g –v e  p a t i en t s  w i t h  DN A  lo ads  >  2 0 , 00 0  IU / m L.  
c .  P r es ence  o f  ch ron i c  l i v e r  d i s ea s e  i r r e s p ec t iv e  o f  D N A l ev e l s  
N u c l eos ( t ) i d e  an a logu es  t h a t  w e r e  g iv en  t o  p a t i en t s  i n c lu ded  t eno fo v i r  
( 3 00  m g  on ce  d a i l y) ,  en t ecav i r  ( 0 . 5  mg  o n ce  d a i l y)  o r  l am iv ud i n e  ( 10 0  
m g  on ce  d a i l y) / ad ef o v i r (5  m g  on ce  d a i l y) . H BeA g +  p a t i en t s  w e r e  g i v en  
e i t h e r  p egi n t e r f e r on  a l ph a  2  a /b  o r  con v en t io n a l  i n t e r f e ro n  a lp h a  5  
m i l i on  s / c  u n i t s  t h r i c e  w eek l y u p t o  6  m on th s .  O u r  dep a r tm en t  po l i cy 
w as  to  o f f e r  i n t e r f e r o n  th e r ap y f o r  e  an t i gen  po s i t i v e  p a t i en t s .  e  
an t i gen  n ega t iv e  p a t i en t s  w e re  n o t  co ns id e r ed  fo r  i n t e r f e ro n  th e r ap y 
d u e  to  l o w  s u ccess  r a t es  i n  t h i s  g r ou p .   
•  Inclusion Criteria  
  C h ro n i c  h ep a t i t i s  B  p a t i en t s  i n i t i a t ed  o n  an t i v i r a l  t he r apy (  
i n c lu d i n g  c i r rh os i s )  
•  Exclusion Criteria  
  A cut e  h ep a t i t i s  B  
   Co -  i n f ec t i on  wi t h  h ep a t i t i s  C  an d  H IV  
   P r io r  an t i v i r a l  t he r ap y   
In s t i t u t io n a l  r es ea rch  co mmi t t e e  ap p rov ed  th e  s t ud y an d  i t  was  
co nd u c t ed  i n  a cco rd a n ce  wi t h  d ec l a r a t i on  o f  H e l s i nk i .  Wr i t t en  i n f o rm ed  
co ns en t  w as  t ak en  f r o m pa r t i c i pan t s ,  p r i o r  t o  en r o lm en t  i n  s tu d y.  A l l  
p a t i en t s  u nd e r wen t  c l i n i ca l  ex am in a t ion  an d  b l oo d  t e s t s  i n c lu d in g  l i ve r  
f u n c t i on  t es t s ,  p r o th om bi n  t im e  wi th  IN R,  a l ph a  f e t o p r o te i n ,  H B s A g,  E  
an t i gen ,  q u an t i t a t i ve  H BV  D N A P CR,  q H Bs A g and  u l t r aso u nd  
ex amin a t io n  on  i n i t i a l  ev a lu a t io n .  IgM  co r e  w as  d on e  w h en  ev id ence  o f  
ch r on i c i t y  w as  n o t  c l e a r .  T h e rea f t e r  pa t i en t s  un de r w en t  qu an t i t a t i v e  
H BV  D NA  PCR ,  qH Bs A g,  A LT  o n  f o l l o w up  v i s i t s  a t  3  t o  6  m on th s , 12  
an d  18  m on ths .  W e w an t ed  t o  hav e  a t l e a s t  2  fo l lo w  u p  v i s i t s  . M ax imu m 
f o l lo w  u p  o f  p a t i en t s  w as  a t  18  m on ths .  Ch r i s t i an  Med i ca l  Co l l ege  f lu id  




C h ron i c  H ep a t i t i s  B :  A l l  p a t i en t s  wi th  H Bs A g po s i t i v i t y  f o r  m o r e  t h an  
6  m on th s  o r  p a t i en t s  wi t h  H BsA g po s i t i v i t y  w i th  n ega t i ve  IgM  co r e .  
C i rrho s i s  o f  l i v er :  A l l  p a t i en t s  wi t h  c l i n i ca l ,  b i o ch em ica l  ( l o w  
a l bum in  an d  e l ev a t ed  P T  wi t h  IN R )  ev i d en ce  o f  C LD  co n f i rm ed  b y 
e i t h e r  r ad io l o g i ca l  ( u l t r as ou nd  sh o wing  s h ru nk en  l i v e r  wi t h  h ep a t i c  
n o du l e s  o r  p o r t a l  ve i n  >13m m)  o r  en do s co p i c  ev i d en ce  o f  po r t a l  
h yp e r t ens io n  o r  h i s t o l o g y  
V i ro lo g i ca l  r esp ons e  (V R ) :  P at i en t s  w i t h  ≥  2  l o g  dec l ine  in  H BV  DN A  
a t  2 4  w eek s .  
C o mpl e t e  V iro l og ica l  r es pon se  (C V R) :  P a t i en t s  wi th  u nd e t ec t ab l e  (n i l  
o r  <  10 )  H BV  D N A l ev e l s  a t  2 4  w eek s .  
N on R es pon se ( N R) :  P a t i en t s  w i th  <  1  lo g  r edu c t io n  i n  D NA  lev e l s  a t  2 4  
w eeks .  
Laboratory tests : 
 Ro u t i n e  b lo od  t e s t s  i n c lu d i n g  s e ru m a l an in e  ami no t r ans fe r a s e  ( A LT ) ,  
a l bum in ,  b i l i r ub in  an d  c r ea t i n i n e  l ev e l s  w e r e  m easu r ed  us in g  au to m at ed  
an a l ys e r .   
S ero lo gy  te s t in g  
H Bs A g q u an t i f i ca t i on  w as  p e r fo r med  us in g  th e  A r ch i t e c t  
ch emi l umi n es cen t  s ys t em ( Ab bo t t ,  We i sb ad en ,  G er man y) . Th e  d yn am ic  
r an ge  o f  t h e  a s s ay  i s  b e tw een  0 . 05  to  25 0  IU / m L.  S amp l es  w i th  >2 50  
IU / m L w er e  d i l u t ed  a t  1 : 20  and  1 : 50 0  w i t h  t h e  Ar ch i t e c t  H Bs A g d i lu en t  
an d  t e s t ed .  S am ple s  w i th  >12 5 ,0 00  IU / m L w er e  f u r th e r  t e s t ed  wi t h  
1 :9 99  d i lu t io n .   
H BeA g an d  an t i -HBc  t e s t i n g  w as  p e r fo r med  in  an  enz ym e  i mm un o ass a y  
( D i as o r in  S .P .A . ,  S a l u gg i a ,  I t a l y)  a cco r d in g  t o  t he  m anu f ac t u r e r s  
i n s t r u c t i on .  T h e  u p pe r  l imi t  d e t ec t io n  ( U LD )  o f  as s ay a f t e r  t h e  
r e com m en ded  d i lu t i on  i s  25 00 00  IU / mL.  
 
HB V  D N A quan t i f i ca t i on   
D N A  w as  i s o l a t ed  f r om  p l asm a  s amp l e  us in g  th e  au t om at ed  m2 00 0sp  
s ys t em  ( Ab bo t t ,  W ei s b ad en ,  G e rm an y) .  T h e  i s o l a t ed  D N A  w as  th en  
q u an t i f i ed  us i n g  th e  m 20 00 r t  s ys t em ( Ab bo t t ,  W ei s b a d en ,  
G e r m an y) . Lo w es t  l i mi t  o f  d e t ec t i on  i s  10  IU / m l .  Al l  l ab o r a to r y a s s a ys  









Statist ical  Analysis  
S e ru m su r f ace  an t igen  and  H BV  DN A  l ev e l s  we r e  lo ga r i t h mi ca l l y  
t r an s fo rm ed  f o r  ana l ys i s .  C on t in uo us  v a r i ab l es  a r e  p r e s en t ed  as  m ean  
( ±S D )  o r  m ed i an  ( in t e r - qu a r t i l e  r an ge  [ IQ R] ) ,  wh e r e  app ro p r i a t e  
C on t in uo us  v a r i ab l e s  we r e  com p a red  us in g  th e  t  t e s t  o r  t he  M an n -
Wh i tn e y U  t es t  an d  c a t ego r i ca l  v a r i ab l e s  we r e  com p a red  us in g  t h e  χ 2  o r  
F i sh e r  ex ac t  t e s t .  Sp ea rm an ’s  co r re l a t i o n  co e f f i c i en t ( r )  was  u s ed  to  
d e r i v e  co r r e l a t i on  b e tw een  t w o  v ar i ab l e s .   
 S t a t i s t i c a l  an a l ys e s  w er e  p e r fo rm ed  us in g  SP SS ,  v e r s io n  2 0 .0  (S PSS ,  
C h i cago ,  IL) .  A l l  s t a t i s t i c a l  t e s t s  w e re  2 - s id ed  an d  p  v a l ue  o f  >0 . 05  















                                           
 













 T ot a l  o f  8 8  p a t i en t s  w er e  s t a r t ed  on  an t i v i r a l  t h e r ap y b e tw een  J an  2 01 1  
an d  D ecem ber  2 01 2 .  F i f t y  f i v e  p a t i en t s  h ad  f o l l ow  u p  a t  6  m on th s ,  
t w en t y e i gh t  p a t i en t s  h ad  f o l l o w up  a t  1  yea r  and  11  p a t i en t s  h ad  
f o l lo w  u p  a t  1 8  mon th s .  A  t o t a l  o f  1 81  s ampl e s  w e r e  an a l ys ed  
 Bas e l i n e  c l i n i ca l  an d  l ab o ra to r y p a r am et e r s  a r e  d ep i c t ed  in  t ab l e  1 .  
M a jo r i t y  o f  p a t i en t s  w er e  f r om  E as t e rn  In d i a  ( 48 .8 6 %) .  Fo r t y e i gh t  
p a t i en t s  w e r e  H BeA g – v e  (5 4 . 54 % )  an d  f o r t y p a t i en t s  we r e  H BeA g +v e  
( 4 5 . 46 % ) .  M a jo r i t y  ( n =7 8 )  w er e  m al e s  w i th  m ed i an  age  o f  36 .5 0  ( 7  -6 9 )  
yea r s .  M ed i an  b as e l in e  AS T and  A LT  w er e  3 9  ( 9 - 12 04 )  an d  4 1  (8 -
1 5 18 ) . M ed i an  b as e l i n e  qH Bs A g  an d  HBV  D N A l ev e l s  wer e  l o g 1 0  3 .9 8  
( 0 .1 9  –  5 . 40 )  IU  /mL an d  lo g 1 0  5 .3 9 (1 .1 5  - 9 . 90 )  IU / m L r e s p ec t i v e l y .  In  
H BeA g +  v e  p a t i en t s ,  b a se l in e  q H BsAg an d  H BV  D N A lev e l s  w e r e  
l o g 1 0  4 . 35 ( 2 . 89  -5 .4 0 )  IU / m L an d  l o g 1 0  6 . 70 ( 2 . 62 -9 .9 0 )  IU /m L 
r e s p ec t iv e l y an d  i n  H BeA g -v e  p a t i en t s  t h ey w e r e  lo g 1 0  3 . 7 11  ( 0 . 19  -
5 . 07 )  IU / m L an d  l og 1 0  4 . 00  (1 .1 5  -  9 .00 )  IU / m L r e s p ec t ive l y .  Bas e l in e  
H BV  D NA  an d  qHBs A g l ev e l s  w e re  s i gn i f i can t l y h i gh e r  i n  e  an t i gen  
p os i t i v e  p a t i en t s  as  com p ar ed  to  e  an t igen  n ega t iv e  ca s es  ( P  <  0 .0 00 1 ) .  
M ed i an  du r a t i on  o f  f o l l o w up  o f  s t ud y p op u l a t i on  was  12  m on th s  (6  t o  
1 8  mo nt hs ) .  
A m on g  ba s e l i n e  cha r ac t e r i s t i c s  f o l l o wi n g  p a r am et e r s  co r re l a t e d  wi th  
q H Bs A g 
a .  DN A:  ( r = 0.487, p <   0.01) 
T h e r e  w as  n o  co r r e l a t i o n  o f  A LT  wi th  b a s e l i n e  qH Bs A g( r=0 .1 18 ,  p  
=0 .2 75 ) .  
Table 1-Comparison of Baseline Characteristics between e 
antigen positive and negative patients 
Characteristics TOTAL 
(N=88) 
e  ANTIGEN +  
(N=40) 






  36.50  (7 - 69)     30  (7 -  63 ) 41 ( 19 - 69) 0.0001 







 43 (48.86) 
 12 (13.64) 
 22 (25) 
 10 (11.36) 
   
AST 
Median(range) 
  39  (9-1204)    43.50 (16-96)     33   (9-1204) 0.022 
ALT 
Median(range) 
  41  (8-1518)     46  (8-889)     31  (10-1518) 0.001 
DNA log10 IU/Ml  5.39 (1.15 -9.90)   6.70(2.62-9.90)  4.00(1.15 - 9.00) 0.0001 
qHBsAg  log10 
IU/mL 







      
     39(44.32) 
     33(37.5) 
      8 (9.09) 
      8 (9.09)   
 
   18(45) 
   12(30) 
    2 (5) 
    8 (20) 
 
      21 (43.75) 
      21 (43.75) 
        6 (12.5) 
        0 (0) 
 
CIRRHOSIS(%)       32 (36.36)     13(32.5)        19(39.58)  
 
 
Correlation between HBV DNA and Surface antigen 
levels  
T h e r e  w as  co r r e l a t i o n  n o t ed  b e t w een  H BV  D NA  an d  qHBs A g l ev e l s  a t  
b a s e l i n e  and  a t  24  w eeks  o f  t he r ap y i n  e  an t i gen  po s i t i v e  ca s e s  as  
s ho w n i n  T ab l e  2 .  Bas e l in e  q H BsA g s i gn i f i can t l y co r r e l a t ed  wi t h  H BV  
D N A  l ev e l s  wi th  a  co r r e l a t i o n  coe f f i c i en t ( r )  o f  0 . 48 7  ( p  <  0 .0 1 ) .Wh en  a  
s ub gr o up  an a l ys i s  w as  n o t ed  i n  e  an t igen  po s i t i v e  and  n ega t iv e  p a t i en t s  
s i gn i f i c an t  co r r e l a t i on  b e t w een  t h es e  tw o  t es t s  w as  a l so  no t ed  in  e  
an t i gen  po s i t i v e  p a t i en t s ( r  =0 .5 60 ,  p  <0 . 01 )  a s  op po sed  to  e  an t i gen  
n ega t i v e  p a t i en t s ( r=0 .2 56 ) .Co r r e l a t ion  be tw een   s u r f ace  an t i gen  and  
H BV  D NA  was  m ain t a in ed  a f t e r  6  mo n t hs  o f  an t i v i r a l  t he r ap y 
( r =0 .3 44 ,p  <  0 .0 5 )  i n  e  an t i gen  pos i t i ve  p a t i en t s .  T he r e  was  n o  
co r r e l a t i o n  no t ed  a t  4 8  w eek s ( r  =0 .3 59 ,  p =0 .0 8 ) i n  e  an t igen  po s i t i v e  
an d  n ega t iv e  p a t i en t s ( r =0 . 42 5 , p =0 .1 68) . In  H BeA g - v e  ca se s  t he r e  w as  
ex ce l l en t  co r r e l a t i on  no t ed  a f t e r  18  m on th s  o f  t h e rap y( r =0 . 8 94 ,  p=0 . 05 )  
  
Table 2:  Correlation between HBV DNA and qHBsAg 
    All patients 
 rho               p value 
E  antigen positive 
rho                p value 
E antigen negative 
rho                p value 
24 weeks 0.344             0.05 0.427                0.05 0.146             0.433 
48 weeks 0.359             .085 0.014                0.966 0.425             0.168 
72 weeks 0.426              .252 0.600                   0.4 0.894              0.05 
 
 
Correlation of qHBsAg with HBV DNA levels with type of 
antiviral therapy. 
 
M ajo r i t y  w e r e  s t a r t ed  o n  t en of ov i r  (4 4 . 3 7% )  f o l lo w ed  b y en t ecav i r  
( 3 7 . 5 %)  an d  l ami vud in e / +  ad e fo v i r  ( 9 .0 9  % )  o r  i n t e r f e ro n  th e r ap y 
( 9 .0 9 %) .  Com pl i ance  to  an t iv i r a l  t he rap y w as  en su r ed  o n  ev e r y f o l l o w 
u p .  No  ad v er s e  d r ug  e f f ec t s  l e ad i n g  t o  d i s co n t i nu a t io n  o f  an t i v i r a l  
t h e r ap y w e r e  n o t ed  o n  fo l lo w  u p .  N one  o f  t h e  p a t i en t s  h ad  de r an ged  
r en a l  p a r am et e r s  on  t eno f ov i r  t h e r ap y . Bas e l in e  co r re l a t i o n  b e t w een  
H BV  D NA  an d  qHBs A g l ev e l s  w e re  no t ed  o n  en t ecav i r  (E T V )  and  
t eno fo v i r  ( T D F)  t he r ap y w i t h  co r r e l a t i on  co e f f i c i en t  ( r )  o f   0 . 42 8  ( p  <  
0 . 00 5)  an d  0 . 56 7  (  p  <  0 . 00 1 ) (S ee  t ab l e  3 ) .C o r re l a t i on  w as  m ai n t a i n ed  
o n  en t ecav i r  t h e r apy a t  6  mo n t hs  b u t  no t  on  t en o fo v i r  o r  i n t e r f e ro n  
t h e r ap y.  T h e r e  w as  n o  co r r e l a t i o n  a f t e r  on e  yea r  o f  t h e rap y w i th  e i t h e r  
en t ecav i r  o r  t eno f ov i r  t h e rap y.  T h e r e  w as  s i gn i f i can t  co r r e l a t i on  
b e tw een  t h es e  t e s t s  a t  1  yea r  o n  in t e r fe r o n  t h e r ap y.  
M ed i an  qH Bs A g and  H BV D NA  a t  b ase l i n e ,  2 4  w eek s ,  4 8  w eeks  and  7 2  
w eeks  o n  E TV  t h erap y w as  l o g 1 0  3 . 73  an d  lo g 1 0  5 .9 5 ,  l o g 1 0  3 . 79  and  
l o g 1 0  1 . 65 ,  l o g 1 0  3 .4 6  and  l o g 1 0  1 . 45  an d  lo g 1 0  3 .1 1  and  lo g 1 0  1 . 00  
r e s p ec t iv e l y .  
M ed i an  qH Bs A g and  H BV D NA  a t  b ase l i n e ,  2 4  w eek s ,  4 8  w eeks  and  7 2  
w eeks  o n  T D F th e rap y w as  l o g 1 0  4 . 16  an d  lo g 1 0  5 .3 0 ,  l o g 1 0  4 . 29  and  
l o g 1 0  1 . 72  ,  l o g 1 0  4 .0 6  and  l o g 1 0  1 . 23  an d  lo g 1 0  4 .1 5  and  lo g 1 0  1 . 32  
r e s p ec t iv e l y  
 
Table 3 Correlation with Antiviral  the rapy 
D u r a t i o n        ET V 
rho              p value 
     TD F 
rho                p value 
          I FN  
rho               p value 
 
 
2 4  w eeks  
4 8  w eeks  
7 2  w eeks  
 
 
0 . 49 6       <0 . 05  
0 . 55 9       0 .1 17  
 
 
0 . 22 6       0 .2 77  
0 . 19 0       0 .5 77  
0 . 88 0       0 .2 20  
 
 
0 . 80          0 .1 04  
0 . 96 2       <  0 .0 05  
 
  qHBsAg and HBV DNA Decline with therapy 
T h e r e  w as  n o  s i gn i f i c an t  d i f fe r en ce  i n  q H Bs A g a t  v a r i ou s  t im e  p o i n t s  
d u r i n g  th i s  s t ud y.  ( S ee  T ab l e  4 )  
Table 4:  qHBsAg and HBV DNA levels  
 Bas e l in e  2 4 w eeks  4 8 w eeks  7 2  w eeks  P  v a l u e  
q H Bs A g ( lo g 1 0  IU / m l )  3 . 98  ( 0 . 19  t o  
5 . 40 )  
4 . 24  
( 0 .1 9  to  
5 . 38 )  
3 . 82 3  (0 .2 6  
t o  4 . 98 )  
3 . 82 (2 .9 8  
t o  4 . 58 )  
0 . 41 9  
H BV  D NA (l o g 1 0  
IU / ml )  
5 . 39 (1 .1 5  to  
9 . 90 )  
1 . 67 (1 .0 0  
t o  7 . 70 )   
1 . 59  ( 1 . 00  
t o  6 . 00 )  
1 . 23 (1 .0 0  
t o  7 . 00 )  
<0 .0 5  
q H Bs A g ( H b eA g+ )  
( l o g 1 0  IU / m l )  
 
            ( H BeA g - )  
4 . 34 (2 .8 9  to  
5 . 40 )  
 
3 . 71 (0 .1 9  to  
5 . 07 )  
4 . 36 (2 .0 9  
t o  5 . 38 0 )  
 
3 . 61 (0 .1 9  
t o  4 . 92 )  
4 . 16  ( 0 . 26  
t o  4 . 98 )  
 
3 . 34 (0 .4 1  
t o  4 . 65 )  
3 . 96  ( 3 . 30  
t o  4 . 23 )  
 
3 . 24  ( 2 . 98  
t o  4 . 58 )  
0 . 55 2  
 
0 . 42 1  
 
  
I t  ch an ged  f r om  log 1 0  3 .9 8  ( 0 . 19  to  5 .4 0 )  a t  ba s e l i n e  t o  l o g 1 0  4 .2 4  ( 0 . 19  
t o  5 . 38 )  a t  6  mo n ths  . I t  d ec l in ed  to  l og 1 0  3 .8 23  (0 .2 6  t o  4 . 98 )  a t  12  
m on th s  an d  r em a ined  s t ab l e  a t  l o g 1 0  3 . 8 2( 2 . 98  t o  4 . 58 )  a t  1 8  m on th s .   
H BV  D NA  s i gn i f i can t l y  d ec l in ed  f ro m lo g  5 . 39 ( 1 . 15  to  9 .9 0 )  t o  l o g 1 0  
1 . 67 (1 .0 0  to  7 .7 0 )  ( p  <  0 . 05 )  a t  6  mo n t hs .  I t  w as  lo g 1 0  1 .5 9  ( 1 . 00  t o  
6 . 00 )  a t  12  mo nt hs  an d  th e  lo w es t  a t  18 mo nt hs  1 .2 3 ( 1 . 00  t o  7 . 00 )  ( See  
F i g  1 ) .  
 
               Fig -1 Median HBV DNA and qHBsAg levels  
  
HB eA g +v e  
In  e  an t i gen  p os i t i ve  p a t i en t s  q H Bs A g ch an ged  f ro m l o g 1 0  4 .3 4 ( 2 . 89  t o  
5 . 40 )  t o  l o g 1 0  4 . 36 (2 . 09  to  5 .3 80 )  a t  6  m on th s .  I t  t h en  d ecr ea s ed  t o  
l o g 1 0  4 . 16 4 5  (0 .2 6  t o  4 . 98 )  a t  12  m onth s  and  l ow es t  a t  18  mo nt hs  l o g 1 0  
3 . 96  ( 3 . 30  t o  4 . 23 ) .  In  t h i s  su b gr ou p  o f  p a t i en t s  l o g  H BV  D N A  
d ec r eas ed  s i gn i f i c an t l y f r om  l o g 1 0  6 . 70 ( 2 . 62  t o  9 . 90 )  a t  ba s e l in e  t o  
l o g 1 0  3 . 00 (1  t o  7 . 70 )  a t  6  m on th s  (p <  0 . 0 5) .  I t  f u r t h e r  r edu ced  to  l o g 1 0  
2 . 38 (1 .0 0  to  6 .0 0 )  a t  1 2  m on th s  . I t  chan ged  t o  l o g 1 0  3 . 30( 1 .0 0  to  7 .0 0 )  
a t  1 8  m on th s .  (  s ee  f i g  2 ) .  
 
 
HB eA g -v e  
In  e  an t i gen  n ega t iv e  p a t i en t s  l o g  qHBs A g d ec l i n ed  f r om  b ase l i ne  l o g 1 0  
3 . 71 (0 .1 9  to  5 .0 7 )  t o  l o g 1 0  3 . 61 ( 0 . 19  to  4 . 92 )  a t  6  m on th s .  I t  t h en  
s t ab i l i s ed  to  l o g 1 0  3 . 34 (0 .4 1  to  4 .6 5 )  a t  1 2  m on th  an d  l og 1 0  3 .2 4  ( 2 . 98  
t o  4 . 58 )  a t  18  m onth s .  In  e  an t i gen  n ega t iv e  p a t i en t s  H BV  D NA  
d ec l in ed  f ro m l o g 1 0  4 .0 0  (1 .1 5  to  9 .0 0 )  t o  1 .1 0 (1 .0 0  t o  6 . 00 )  a t  6  
m on th s .  I t  s t ab i l i s ed  t o   l o g 1 0   1 . 04 (1 .0 0  to  4 .9 0 )  a t  1 2  mo nt h  and  lo g 1 0  
1 . 00 (1 .0 0  to  1 .4 1 )  a t  1 8  m on th s . ( f i g3 )  O v er a l l  D N A dec l in e  w as  
s i gn i f i c an t l y d i f f e ren t  a t  a l l  t i m e  po i n t s  i n  e  an t i gen  po s i t i v e  and  
n ega t i v e  p a t i en t s ( p<  0 . 05 )  as  com p a r ed  t o  q H Bs A g l eve l s .             
  
 
Fig 2 Median HBV DNA and qHBsAg levels in HBeAg +ve patients 
 
Fig 3 Median HBV DNA and qHBsAg levels in HBeAg -ve patients 
 V i ro lo g i ca l  r esp ons e  (V R ) :   
7 2 .7  %  (n =40 )  p a t i en t s  a ch i eved  v i r o lo g i ca l  r esp on s e .  Un iv a r i a t e  
an a l ys i s  s ho w ed  t ha t  t h a t  b as e l i n e  q HBs A g,  H BV DN A ,  A LT ,  age  o r  
s ex  w e r e  no t  p r ed i c t o r s  o f  v i ro lo g i ca l  r e s po ns e .  q H Bs A g an d  H BV  D N A 
a t  b as e l in e  i n  t ho s e  w ho  ach i ev ed  V R w er e  l o g 1 0  5 . 85  (1 .6 3  to  9 .9 0 )  
an d  lo g 1 0  4 .0 8  ( 0 . 19  t o  5 . 40 ) IU / m L . In  H BeA g +  v e  VR p a t i en t s ,  i t  w as  
l o g 1 0  4 . 64  ( 3 . 52  t o  5 . 40 )  and  l o g 1 0  7 .66 ( 4 . 78  t o  9 . 90 ) IU / m L r e s p ec t i v e l y 
an d  in  H BeA g –v e  V R p a t i en t s  ,  i t  w as  l o g 1 0  3 . 64  (0 .1 9  to  4 . 78 )  and  
l o g 1 0  4 . 30  (1 .1 5  to  7 . 30 ) IU / m L . In  e  an t i gen  po s i t i v e  p a t i en t s  o n l y 
H BV  D NA  was  p r ed i c to r  o f  v i r o lo g i ca l  r e sp on s e (P   <  0 . 05 ) .  
 
C o mpl e t e  v i ro l og ica l  r es pon se  (C V R) :  
A m on g  pa t i en t s  w ho  ach iev ed  v i r o l o g ica l  r e sp on s e ,C VR  w as  n o t ed  i n  
1 8  p a t i en t s  (2  i n  HBeA g +v e  an d  16  in  Hb eA g –  v e  p a t i en t s ) .O n  
u n i v ar i a t e  an a l ys i s ,  b as e l in e  A LT  an d  l o g  H BV  DN A  w ere  p r ed i c to r s  o f  
C VR  ( p  <  0 .0 5 )  .  qH Bs A g w as  n o t  a  p r ed i c to r  o f  C VR ( p  =  0 . 05 7 ) .  O n  
m ul t iv a r i a t e  an a l ys i s  on l y b a s e l in e  HBV  D N A w as  s i gn i f i c an t  p r ed i c t o r  
o f  C VR. A UC  f o r  p red i c t i n g  C VR w as  lo w es t  f o r  q H Bs A g a t  0 .6 59 ,  
f o l lo w ed  b y A LT  a t  0 .7 21  and  h i gh es t  f o r  H BV  D N A a t  0 . 8 1 9( s ee  F i g  
5 ) .M ed i an  b a s e l i ne  q H Bs A g an d  H BV  D N A  in  t ho s e  wh o  ach iev ed  C VR 
w er e  l o g 1 0  3 . 72 ( 0 . 19  t o  5 . 06 )  an d  l o g 1 0  3 . 77 ( 1 . 15  to  6 .3 0 )  IU / m L 
r e s p ec t iv e l y.  D i f f e r en ce  in  q H BsA g( Δ q H Bs A g)  a t  2 4  w eek s  w as  l o g 1 0  
0 . 04 8  IU / ml .  In  H BeA g +  pa t i en t s ,  m ed i an  b a se l in e  q H BsA g an d  H BV 
D N A  w er e  lo g 1 0  4 .40 ( 3 . 31  t o  5 . 40 )  and  6 .6 0 ( 3 . 30  t o  9 . 90 )  IU / m L 
r e s p ec t iv e l y.  Δ  q HBs A g in  t h i s  g ro up  w as  0 .2 3 .  In  H BeAg –  ve  p a t i en t s  
m ed i an  b a s e l i n e  qHBs A g and  H BV  DNA  w er e  l o g 1 0  3 .6 4 (0 . 19  to  4 .5 3 )  
an d  lo g 1 0  3 .7 0 (1 .1 5 - 6 .3 0 )  IU / m L r e s p ec t i v e l y.  Δ  q H Bs A g i n  t h i s  g r o up  
w as  0 .0 42 .  
 
 
N on  Resp ons e :  
1 3  p a t i en t s  w er e  n on  r es po nd e rs  (2 3 . 21 % ) .E i gh t  p a t i en t s  w e r e  e  an t i gen  
n ega t i v e  and  f iv e  pa t i en t s  w er e  e  an t igen  po s i t i v e .  Un iv ar i a t e  an a l ys i s  
s ho w ed  t h a t  t h a t  b as e l in e  q H BsA g,  H BV  D NA  o r  A LT  w er e  no t  
p r ed i c t o r s  o f  no n  re s po ns e .  qH Bs A g an d  H BV  D N A a t  bas e l in e  i n  t ho s e  
w h o  ach i ev ed  VR  w er e  l o g 1 0  3 .4 9 (0 .19  t o5 .4 0 )   and  lo g 1 0  4 .6 0 ( 1 . 15  t o  
7 . 78 ) IU / m L.  A mo ng  t h i s  s ub gr o up  o f  p a t i en t s ,  f i v e  w er e  o n  T D F and  
IFN  each  ,  t wo  p a t i en t s  r e ce i v ed  LA M  an d  on e  o n  ET V  t he r ap y.  
 





ALT levels and correlation with qHBsAg: 
M edi an  A LT  l ev e l s  a t  b as e l i n e ,  2 4  w eek s ,  4 8  w eek s  and  7 2  w eeks  w e r e  
4 1  ( 8  to  1 51 8) ,  33 .5 0  ( 9  to  5 74 ) ,  3 3 (16  t o  22 3 )  and  4 3  (30  t o  86 )  
r e s p ec t iv e l y.  In  H Be A g +  ve  g r ou p  med i an  A LT  l ev e l s  wer e  46  (8  to  
8 8 9) ,  32  (9  t o  2 27 ) ,  33 (1 6  to  2 23 )  and  5 3 . 5 ( 42  t o  86 )  r e sp ec t iv e l y.  In  
H BeA g –  v e  g r o up  m ed i an  A LT  l ev e l s  w e r e  3 1  ( 10  to  1 518 ) ,  34 .5  (1 0  t o  
5 7 4)  ,  3 1 . 5  ( 16  to  78 ) ,3 0 . 5 (  30  to  3 1 ) . (S ee  F i g  4 ) .T h er e  was  n o  
co r r e l a t i o n  o f   A LT  w i th  q H BsA g  a t  ba s e l in e ,  24  w eeks ,48  w eeks  an d  
7 2  w eeks .  Th e r e  was  n o  s i gn i f i c an t  d i f f e r en ce  i n  d i s t r i b u t io n  o f  A LT  




            Fig4. ALT levels in HBeAg + and HBeAg - patients 
 
 
P=0.656 and 0.345 for HBeAg + and 
HBeAg –ve   
Interferon Therapy: 
E i gh t  p a t i en t s  w e r e  s t a r t ed  on  in t e r f e ro n  th e r ap y.  O n e  p a t i en t  r e ce iv ed  
t h e r ap y f o r  4 8  w eek s  and  h e  h ad  e  an t i gen  s e ro con v er s i on .  S ev en  
p a t i en t s  h ad  f a i l ed  i n t e r fe r on  t he r ap y an d  r ece i v ed  th e r apy f o r  a t l e as t  6  
m on th s .  q H Bs A g an d  H BV  D N A t r ends  i n  t h es e  p a t i en t s  a r e  dep i c t ed  in  
f i g  5 .  M ed i an  q H BsA g an d  H BV D NA  a t  b as e l in e ,1 2  w eeks ,2 4  w eek s  
an d  48  w eeks  o n  IF N  th e r ap y w as   l o g 1 0  3 .9 1  and  l o g 1 0  6 .0 4  ,  l o g 1 0  4 .4 1  
an d  lo g 1 0  5 .6 9  ,  l o g 1 0  3 . 40  an d  l o g 1 0  4 .7 7   an d  lo g 1 0  3 .8 2  an d  lo g 1 0  5 .9 5  
r e s p ec t iv e l y.  q H BsA g an d  H BV D NA  d ec l in e  p a t t e r ns  i n  p a t i en t  wh o  











 Fig 6: qHBsAg and HBV DNA trend on successfully treated interferon therapy patient 

























Availabil i ty of quanti tat ive HBsAg assays has renewed the interests of 
hepatologists worldwide. Many studies involving subjects from var ious ethnicit ies 
have been done. It is accepted that qHBsAg tends to be higher in patients who 
are HBeAg positive and low replicators can be identified with   qHBsAg 
<1000 IU/ml (20) in genotype D patients.  The data on qHBsAg dynamics on 
NA treatment is scarce and variable.  Our aim was to look at  the patterns of 
decline in qHBsAg level during antiviral therapy and i ts correlation with 
HBV DNA levels.  
The clinical utility of qHBsAg in IFN treated patients is accepted and 
variable reductions have been shown to predict response  to IFN. More 
reliably,  non responders can be identified as early as 12 weeks,  with lack of 
qHBsAg reduction (37,41,42).  In our study 7/8 patients treated with IFN did 
not show any virological response  (neither end of treatment nor sustained) . In 
these patients, there was no decrease  of qHBsAg was seen at any time point 
throughout  the treatment. In fact , the levels increased before reaching the 
baseline value.  In the single patient who responded also, the qHBsAg levels 
showed no reduction at  all  time points . Thus our study clearly shows that 
monitoring qHBsAg is useful in predicting non response to IFN . It is difficult  
to explain why the single responder also did not show any reduction in 
qHBsAg. Some studies have also looked at the baseline level  of qHBsAg < 
10,000 IU/L in predicting response to IFN (42).  Our IFN responder did not 
have different baseline qHBsAg compared to non responders . Baseline 
qHBsAg level in patients who responded and non responders were log 1 0  3.96 
IU/ml and 3.87 IU/ml respectively.  
Though the exact decline of qHBsAg is not yet agreed upon, any fall in 
qHBsAg at  12 weeks is considered an excellent milestone for deciding on 
continuation of a costly therapy with major side  effects.  Our study also is in 
agreement with these observations ( 37,41,42), - though our numbers are very 
small . Unlike the western country,  in India patients have to pay for their own 
treatment and decision of discontinuation early on makes a major impact on 
the will ingness to even consider this potentially useful but expensive therapy.  
In contrast clinical usefulness of qHBsAg in patien ts receiving oral NA 
therapy had been studied less extensively and results are not reproducible 
among different studies  (27,28,31). There is no published information in this 
regard from India.  Therefore data in this study becomes important as it  
looked at  qHBsAg decline with potent antiviral drugs such as ETV and TDF 
as well with interferon therapy.  
In the case of ENH, where oral NA is preferentially used, the end point of 
therapy is HBsAg clearance. The utility of qHBsAg is mainly to predict the 
durability of viral response once the NA are stopped and to predict who can 
actually be weaned off NA .Patients who had a steep fall in qHBsAg 
commensurate with DNA levels were most likely to achi eve e antigen or S 
antigen clearance subsequently.  This has been shown with telbivudine and 
Tenofovir therapy (30, 31).  Earlier studies also showed a pre ferential  
reduction in qHBsAg levels in e Ag +ve patients (39, 47) 
In HBeAg positive LdT treated patien ts, low qHBsAg levels at  2 years of 
treatment (<100 IU/ml) predicted SR for 2 years after stopping therapy (31).  
In contrast in HBeAg –ve pts,  treated with tenofovir or entecavir,  the decline 
in qHBsAg is not that robust . The early decline has not been sho wn to predict 
long term surface antigen loss in Germans (31) while reduction in qHBsAg 
among LAM users from HongKong could predict sustained viral responders 
(36) 
  
In our study no significant decline in qHBsAg was seen despite 70 % p atients 
showing at  least 2 log reduction in DNA levels.  The qHBsAg levels were not 
reflective of  presence of any viral response , complete response or lack of 
viral response. This leads to the conclus ion that upto a follow up of 18 
months, there are no changes in the hepatocytic  burden of transcriptionally 
active HBV virions.  
The major question in the minds of physicians and  patients alike is the 
duration of NA treatment. At present,  qHBsAg seems to be the only test 
which can predict who can be weaned off with a reasonable chanc e of 
success. Our study tells that atleast  for a period of 18 months  of antiviral 
therapy, no patient either  Eag +ve or –ve showed any sign reduction in 
qHBsAg. No consideration of cessation of NA can be considered until  a trend 
in the reduction of qHBsAg can be shown. Our study reinforces the transient 
nature of NA induced DNA suppression. Though it reduces the inflammatory 
and fibrotic changes in the l iver, it  doesn’t change the natural  history of viral 
kinetics in the body.  
Till qHBsAg reduction is demonstrated, i t  is clear that the immunological 
control of the disease hasn’t  begun and one needs to continue the NA therapy 
with the same vigour  as in the beginning of treatment.  
Advance in the quantification of qHBsAg has opened a new path for further 
understanding of chronic HBV infection. qHBsAg is known to reflect ccc 
DNA, which is the viral  template for  HBV replication in maintenance of 
chronic infection. The correlation between these two markers had been 
studied previously (10, 11). In our study also qHBsAg significantly correlated 
with HBV DNA(r =0.487) at  baseline.  Recent investigations have alluded to a 
potentially interesting aspect of qHBsAg as antigen expression in the natural 
course of HBV infection. Two independent groups found that the level of 
qHBsAg was higher in the immune-tolerant and immune-clearance phases 
than in the low-replicative phase and in patients with HBeAg( -) 
disease(14,19). In HBeAg(+) patients, significant correlation was noted (r ¼ 
0.69, P < 0.001), whereas the association betwe en HBsAg production and 
HBV replication broke down in HBeAg( -)patients (r ¼ 0.28, P ¼ 0.012)(15). 
These reports suggest that the correlation between qHBsAg and HBV DNA 
without antiviral  treatment is more significant in the higher HBV replicative 
phase than in the low-replicative phase. In our study it correlated with HBV 
DNA in HBeAg + (r= 0.560) patients as opposed to HBeAg –ve patients 
(r=0.256) in agreement with other studies at baseline. At 6 months there was 
a weak correlation noted in HBeAg +ve patien ts(r=0.427) as opposed to 
HBeAg –ve patients(r=0.146).In HBeAg –ve patients there was correlation 
noted only after 18 months of therapy (r=0.894)  but numbers were small(five 
patients ).The correlation noted in HBeAg –ve patients is in contrast to 
previous studies done in Hong Kong and Korea involving genotypes B and 
C.(27,28).The possible explanation for this finding may be related to 
genotypic differences .We are not sure of the clinical significance of this 
result . Whether it  predicts a surface antigen cl earance remains to be seen. 
Among different therapies,  r  value  (correlation)  progressively increased in 
ETV and IFN therapy whereas it  decreased on TDF therapy  (see Table 3) . 
Median difference of qHBsAg at 48 weeks with ETV and TDF was not 
significant (log1 0  0.27 and log1 0  0.10 respectively).  There are few 
explanations for this modest  decline of qHBsAg .The possible explanation for 
this modest decline is related to mechanism of action of oral NA which is the 
suppression of viral replication through inhibiti on of HBV polymerase; 
because HBsAg production proceeds by a pathway distinct from that of HBV 
DNA, the effect  of NA on qHBsAg is possibly less prominent.  
A possible explanation for this  lack of correlation between qHBsAg and HBV 
DNA is that the proportion of patients with undetectable or lower HBV DNA 
levels increased with antiviral therapy. Moreover, a modest  decline of 
qHBsAg during ETV and TDF therapy as compared with the rapid reduction 
of HBV DNA was noted, and the result  was the disproportional statu s of 
these two parameters . 
 
HBV DNA and ALT were predictors of complete virological  respon se (CVR) 
on univariate analysis (p<0.05) as compared to qHBsAg (p=0.057).On 
multivariate analysis HBV DNA was only predictor of CVR.  Difference in 
qHBsAg (Δ qHBsAg) a t  24 weeks was log1 0  0.048 IU/ml and Δ qHBsAg in 
HBeAg +ve patients was log1 0  0.23 and Δ qHBsAg in HBeAg –ve patients 
was log1 0  0  .042.HBV DNA,ALT and qHBsAg were not predictors of  partial 
virological response (VR).  
 
There were some limitations of our study.  First ly,  genotypic analysis was not 
done. Previous studies done from our centre demonstrated predominance of 
genotype A and D, and thus our results would be applicable to genotype A 
and D patients (5). Second limitation of this study was that the foll ow-up 
period was short  and none of our subjects had loss of HBsAg  or HBeAg. 
Therefore, the predictive value of quanti tative HBsAg levels for treatment 
induced HBsAg seroconversion cannot be evaluated.  
The majority of CHB patients on antiviral  therapy in our study did not show a 
significant decline in HBsAg levels despi te HBV DNA suppression at  18 
months but the trend needs to be observed over long term.  This is important 
to predict the possibility of eventual cessation of NA, as i t  is  a big financial 
burden for many of our patients.  
Overall  we found negligible reduction in qHBsAg levels as compared to DNA 
with NA consistent with what is described in literature.  This reiterates the 
fact  that HBsAg loss is not very common in patients on NA therapy and 
therapy probably needs to be continued lifelong.  Since decline in qHBsAg 
may predict sustained viral response, it  is  suggested that  this parameter be 
monitored along with DNA levels to look for the emergence of immune 
control of the disease.  
 
 











1.  Absence of any   reduction in qHBsAg levels was associated with 
absence of response to IFN.  
2.  There was no significant reduction in qHBsAg levels after 18 months 
of NA therapy despite significant reduction in DNA levels.  
3.  Baseline HBV DNA level and not qHBsAg level was the only predictor 
of complete virological response.  
4.  No meaningful correlation was noted between qHBsAg and HBV DNA 
levels with either ETV or with TDF therapy.  There was no correlation 
noted between ALT level and qHBsAg level during antiviral therapy.   
5.  The trend of qHBsAg levels needs to be monitored long term along 
with DNA levels while on NA therapy so that  eventual sustained viral  
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3 3 .   J an ss en  H L,  Ke r h o f - Lo s  CJ ,  H e i j t i nk  R A,  S ch a l m SW.  
M easu r em en t  o f  HBs A g to  mo n i to r  h ep a t i t i s  B  v i r a l  r ep l i c a t i on  i n  
p a t i en t s  o n  a l ph a  in t e r f e ro n  th e r ap y.  A n t iv i r a l  R es  19 94 ; 23 :2 51 -2 57 .  
 
3 4 .  M an es i s  E K,  Hadz i yan n i s  ES ,  An ge l op ou l ou  OP ,  Hadz i yan n i s  SJ .  
P r ed ic t i o  o f  t r e a tmen t - r e l a t ed  H Bs A g l os s  i n  H BeA g - n ega t i v e  ch ro n i c  
h ep a t i t i s  B:  a  c l u e  f r om  s e r um H BsA g l ev e l s .  An t iv i r  T he r  20 07 ;1 2 :  
7 3 -8 2 .  
 
3 5 .  Wi egand  J ,  W ed em eye r  H ,  F i n ge r  A ,  H e id r i ch  B ,  Rosen au  J ,  Mi ch e l  
G ,  e t  a l .  A  d ec l in e  i n  h ep a t i t i s  B  v i r us  su r f ace  an t i gen  ( HBs A g)  
p r ed i c t s  c l e a r an ce ,  b u t  d o es  n o t  co r r e l a t e  w i th  q u an t i t a t i ve  H BeA g o r  
H BV  D NA  l eve l s .  A n t iv i r  T h e r  20 08 ;1 3 : 54 7 -5 54 .  
 
3 6 .  Lau  G K,  M ar ce l l i n  P ,  Br un e t t o  M,  P i r a tv i s u th  T ,  K app r e l l  H -P ,  
Bu t t onP ,  e t  a l .  O n - t r ea tm en t  H Bs A g dec l i n e  du r i n g  p eg i n t e r f e r on  a l f a -
2 a ( 40 kD )  6  l am iv ud in e  in  p a t i en t s  w i th  H Bs A g - po s i t i v e  C H B as  
a  po t en t i a l  p r ed i c t o r  o f  du r ab l e  o f f - t r ea tm en t  r e sp on s e  [ Ab s t r ac t ] .  
H EP A TO LO G Y  2 008 ;4 8 (Su pp l ) :7 1 4 A.  
 
3 7 .  S on n ev e l d  MJ ,  R i j ck bo rs t  V ,  Bou ch e r  C A,  H ans en  BE,  J ans s en  H L.  
P r ed ic t i on  o f  su s t a in ed  r e sp ons e  t o  p eg i n t e r f e ro n  a l f a -2 b  f o r  h ep a t i t i s  
B  e  an t i gen -p os i t i ve  ch ro n i c  h ep a t i t i s  B  u s in g  on - t r ea t m en t  h ep a t i t i s  B  
s u r face  an t i gen  dec l in e .  HEP A TO LO G Y  20 10 ;5 2 :1 25 1 -1 25 7 .  
3 8 .   M ar ce l l i n  P ,  Av i l a  C ,  Wu rs th or n  K ,  Ch u an g  W - L,  La u  GK ,  Pen g  C -
Y ,  e t  a l .  T e l b i vu d in e  ( Ld T )  p l us  p eg - in t e r f e ro n  ( p egIFN )  in  H BeA g 
p os i t i v e  ch r on i c  hep a t i t i s  B — v er y p o ten t  an t i v i r a l  e f f i c ac y b u t  r i s k  o f  
p e r i ph e r a l  n eu ro pa th y ( P N ) .  J  H ep a t o l  2 0 10 ; 52 (S up p l  1 ) :S6 -S 7 .  
 
3 9 .  R e i jn d er s  J G P ,  R i j ck bo rs t  V ,  S on nev e ld  MJ ,  Sch e rb e i j n  S MJ ,  
Bo u che r  C A B,  H ans en  BE ,  e t  a l .  K in e t i c s  o f  h ep a t i t i s  B  s u r face  an t i gen  
d i f f e r  b e t w een  t r e a t men t  w i t h  peg i n t e r f e r o n  an d  en t ecav i r .  J  H ep a t o l  
2 0 11 ; 54 :  44 9 - 45 4 .  
 
4 0 .  Br u n e t t o  MR ,  M o r i co n i  F ,  Bon i no  F ,  Lau  G KK ,  Fa r c i  P ,  Y u rd a yd i n  
C , e t  a l .  H ep a t i t i s  B  v i r us  su r f ace  an t i gen  l eve l s :  a  gu id e  to  s us t a in ed  
r e s po ns e  to  p eg in t e r f e r on  a l f a - 2 a  in  HBeA g - n ega t i v e  ch ro n i c  h epa t i t i s  
B .  H EPA T O LO G Y  2 0 09 ; 49 :1 14 1 - 11 50 .  
 
4 1 .  M ar ce l l i n  P ,  P i r a tv i s u th  T ,  Bru ne t t o ,  Bon i no  F ,  Fa r c i  P ,  Y u rd a yd i n  
C , e t  a l .  O n - t r ea tm en t  d ec l i n e  i n  s e r um H Bs A g l ev e l s  p r ed i c t s  su s t a i n ed  
i mmu n e  con t r o l  1  yea r  po s t - t r ea tm en t  an d  su bs equ en t  H Bs A g c l ea r an ce  
i n  H BsA g - n ega t i ve  h ep a t i t i s  B  v i ru s - in f ec t ed  p a t i en t s  t r ea t ed  wi t h  
p eg i n t e r f e r on  a l f a  [ 4 0 kD]  (P E G ASYS ) .  H ep a to l  In t  20 10 ;  4 :1 51 .  
 
4 2 .  C h an  H L,  Wo ng  V W,  Ch im A M,  Ch an  H Y,  Wo n g  G L,  Su n g  J J .  
S e ru m H Bs A g qu an t i f i ca t i on  to  p r ed i c t  r e sp on s e  to  p eg in t e r f e r on  
t h e r ap y o f  e  an t i gen  pos i t i v e  ch r on i c  h ep a t i t i s  B .  Al i m en t  Ph a rm aco l  
T h e r  20 10 ;3 2 :1 32 3 - 1 33 1 .  
 4 3 .   M a  H ,  Y an g  RF ,  W ei  L.  Q uan t i t a t i v e  se r um  H Bs A g an d  H BeA g a r e  
s t ro n g  p r ed ic to r s  o f  su s t a i n ed  H BeA g s e r o co nv e rs i on  t o  peg yl a t ed  
i n t e r fe r on  a l f a - 2b  in  H BeA g -p os i t i v e  p a t i en t s .  J  G as t r o en t e r o l  Hep a t o l  
2 0 10 ; 25 :1 49 8 - 15 06 .  
 
4 4 .  P i r a t v i su t h  T ,  Lau  G K K ,  M ar ce l l i i n  P ,  Br un e t to  M ,  K ap pr e l l  HP ,  
P op es cu  M.  O n - t r ea tm en t  d ec l in e  in  se r um  H Bs A g l ev e l s  p r ed i c t s  
s us t a in ed  i mm un e  co n t r o l  and  H Bs A g c l ea r an ce  6  mo n t h  p os t t r e a tm en t  
i n  H BsA g - p os i t i v e  h ep a t i t i s  B  v i r us - i n f ec t ed  p a t i en t s  t r e a t ed  wi t h  
p e g i n t e r f e r on  a l f a -2 a  [ 4 0k D]  (P EG ASY S ) .  H ep a to l  In t  
2 0 10 ; 4 : 15 2 .  
 
4 5 .  M ou ca r i  R ,  M ack i ew icz  V,  Lad a  O ,  R i p au l t  MP,  C as t e l n au  C ,  
M ar t in o t -P e i gn oux  M ,  e t  a l .  E a r l y s e r um  H Bs A g d r op :  a  s t r on g  
p r ed i c t o r  o f  s us t a ined  v i r o l o g ica l  r es po ns e  t o  p eg yl a t ed  in t e r f e ro n  a l f a -
2 a  i n  H BeA g n ega t iv e  p a t i en t s .  HEP AT O LO G Y  2 00 9 ;  49 :1 1 51 -1 15 7 .   
 
4 6 .  M ou ca r i  R ,  M ar t in o t -P e i gno ux  M ,  M ack i ewi cz  V,  Bo yr  N ,  R ip au l t  
M P,C as t e l nau  C ,  e t  a l .  In f l uen ce  o f  gen o t yp e  o n  h ep a t i t i s  B  su r f ace  
an t i genk in e t i cs  i n  h ep a t i t i s  B  e  an t i gen - n ega t iv e  p a t i e n t s  t r e a t ed  w i th  
p eg yl a t ed  i n t e r f e r on - a l ph a2 a .  An t iv i r  T h e r  20 09 ;  14 : 11 83 - 1 18 8 .  
 
4 7 .  R i j ck bo rs t  V ,  H an sen  BE ,  C ak a l og l u  Y,  Fer en c i  P ,  Tab ak  F ,  
A k do gan  M ,  e t  a l .  E a r l y o n - t r ea tm en t  p r ed i c t i on  o f  r e sp on s e  to  
p eg i n t e r f e r on a l f a -2a  f o r  H BeA g -n ega t iv e  ch r on i c  h e p a t i t i s  B  u s in g  
H Bs A g an d  H BV  DN A  l ev e l s .  H EPA TO LO G Y  2 0 10 ;  5 2 : 45 4 -4 61 .  
 
4 8 .  Yu  M L,  Lee  C M ,  Ch u an g  W L,  Lu  SN ,  D a i  C Y,  H u ang  J F ,  e t  a l .  
H Bs A g p r o f i l e s  i n  p a t i en t s  r e ce i v i n g  p eg i n t e r f e r on  a l f a -2 a  p lu s  
r i bav i r i n  f o r  t h e  t r e a tm en t  o f  du a l  ch ro n i c  i n f ec t io n  wi t h  h ep a t i t i s  B  
an d  C  v i ru s es .  J  In f ec t  Di s  20 10 ;  20 2 :8 6 -9 2 .  
 
4 9 .  Zo u t en d i j k  R ,  Zaa i j e r  H L,  d e  V r i e s -S lu i j s  T E ,  R e i j nd e r s  J G ,  Mul d e r  
J W,  K ro on  FP ,  R ich t e r  C ,  v an  d e r  E i jk  AA ,  So nn ev e ld  MJ ,  H ans en  BE,  
d e  M an  R A ,  v an  d er  En d e  ME ,  J an ss en  H L H ep a t i t i s  B  su r f ace  an t i gen  
d ec l in e s  and  c l ea r an ce  d u r in g  lo n g - t e rm  t en o fo v i r  t h e r apy  i n  p a t i en t s  
co in f ec t ed  wi t h  H BV  and  H IV .  J  In f ec t  Di s .  20 12  S ep  1 5 ;2 0 6  (6 ) : 97 4 -
8 0 .  do i :  10 .1 09 3 / i n f d i s / j i s 43 9  
 
5 0 .  Wo n g  DK  ,  Yu en  M F ,  N ga i  VW e t  a l .  O ne - yea r  en t ecav i r  o r  
l am iv ud in e  th e r ap y r e su l t s  i n  r ed u c t i on  o f  h ep a t i t i s  B  v i ru s  
i n t r ah ep a t i c  cov a len t l y  c l os ed  c i r cu l a r  D N A l ev e l s  .  An t iv i r  Th  e r  























Name HospitalNo Age Sex Eantigen AST ALT
MD Abul Kashem 043589f 45 M NEGATIVE 30 16
Amitabh Chakrabo 617163d 58 M NEGATIVE 41 31
Denis Chandra 965108d 28 M NEGATIVE 27 26
Banladea 819112d 41 M NEGATIVE 26 24
Nagachandra Moul 041154f 42 M NEGATIVE 23 22
Sadanand Biswas 928955D 30 M POSITIVE 61 63
Kajal kumar Bhat 890454d 39 M POSITIVE 38 43
Biswajeet Jana 025434 f 19 M NEGATIVE 47 55
Amarkant Das 991007d 46 M NEGATIVE 23 18
Monoranjan Sarka 023357 F 37 M NEGATIVE 75 39
Mohammed jamil 934272 d 24 M POSITIVE 42 34
Ajit Kumar sarda 886295 d 39 M NEGATIVE 46 59
Uttam Kumar Paul 761307d 48 M NEGATIVE 48 92
Anil Kumar 990711D 29 M NEGATIVE 33 45
Mahendra kumar y 009732f 41 M NEGATIVE 70 96
Niraj Kumar 095502f 24 M POSITIVE 45 37
Abhijit Jana 025428f 17 M POSITIVE 37 48
Ashish Ranjan Si 048166f 30 M POSITIVE 48 62
Akhilanand Singh 047339f 42 M POSITIVE 47 35
Jitendra nath ma 970627d 41 M POSITIVE 104 159
Debasis C 075593F 63 M POSITIVE 35 25
Ajudhia Nath 433743c 67 M NEGATIVE 94 33
Chelo tetup 986801D 62 M POSITIVE 62 47
Moten Naiding 871750d 31 M POSITIVE 81 38
Janaranjan Saha 727929d 55 M NEGATIVE 27 23
Sudhangshu Roy 937846d 69 M NEGATIVE 86 55
MDharoonrashid 104557f 40 M NEGATIVE 29 22
Lalchhantluanga 592888 d 54 M NEGATIVE 22 24
Biri Takar 863531d 21 M NEGATIVE 27 16
Sreenivasa Mohan 888620 d 39 M NEGATIVE 1,204 1,518
Kuppusamy 923126b 37 M NEGATIVE 21 24
Chandra sekar d 915118d 26 M POSITIVE 33 44
Venkata Ramaniah 050920f 35 M NEGATIVE 31 50
SaBIHa Perween 004998f 29 F POSITIVE 37 46
Gopinath Maji 916150d 20 M POSITIVE 151 170
Chandra Bushan Y 911189d 30 M POSITIVE 39 46
Ratan Kundu 062284f 32 M POSITIVE 55 49
Keshav kumar Cho 579007d 21 M POSITIVE 39 91
Jaba Saha 952893d 23 M POSITIVE 121 140
Ata Ravi 048351 f 25 M POSITIVE 35 31
Banumathi 173823d 30 F POSITIVE 59 37
Sita Rani 023133F 48 F NEGATIVE 86 61
Sunil Bhattachar 120624f 48 M NEGATIVE 52 13
Kartik Paul 912028D 59 M NEGATIVE 95 144
Kajol Mondal 017830F 7 M POSITIVE 373 376
Madhu Sudan 026071d 60 M NEGATIVE 23 10
Vishweshwaran 985445d 26 M NEGATIVE 9 14
Sharunnappa Awaj 268894D 42 M NEGATIVE 18 18
Sachu C 289512D 34 F POSITIVE 34 32
Mohoammad Kamal042348F 34 M NEGATIVE 32 29
Farida Yasmin 106098f 37 F NEGATIVE 25 23
Mohammad Saiful 037443f 18 M POSITIVE 30 34
Madhusudan purka 819147d 28 M POSITIVE 30 52
Sankar Rana 973728d 41 M POSITIVE 71 43
Bipin Bihari Raj 024510f 39 M POSITIVE 39 43
Nayan Paul 029480f 31 M NEGATIVE 71 #NULL!
Mantulal Hazra 850079D 36 M NEGATIVE 30 23
Praneet Ansal Mu 952797d 26 M NEGATIVE 326 574
Parimal Podder 867086d 53 M NEGATIVE 107 68
Samar Kumar Bose877576d 50 M NEGATIVE 33 35
Sujit Karmakar 093986f 36 M NEGATIVE 25 32
Badal Dhali 826156d 46 M NEGATIVE 69 31
Abinash das 997425D 53 M POSITIVE 128 57
Bidesh kumar man 134072f 30 M POSITIVE 248 93
Revathi E 102884f 28 F POSITIVE 16 8
Sanat kumar bata 973674d 35 M POSITIVE 42 46
Bablu Mondal 774606d 26 M POSITIVE 46 65
Nabadip Shaw 062133f 37 M POSITIVE 50 41
Goutam Kumar Ban925886d 33 M POSITIVE 500 889
Manoj Kumar 936810d 44 M NEGATIVE 25 20
Aditya kumar s 862504d 52 M POSITIVE 355 115
Biswanath Pradha 016488f 26 M POSITIVE 31 46
Bhanu biswas 982846 D 26 M POSITIVE 25 27
Tamar Baki 994422d 33 M NEGATIVE 35 30
Malamazumdar Das957701d 33 F POSITIVE 976 121
Guraja anand rao 713782c 49 M POSITIVE 31 47
Muruganantham K 073857F 20 M NEGATIVE 35 64
Sagila K 981330C 43 F NEGATIVE 22 23
Mayil Vaganan 108935F 56 M NEGATIVE 81 42
Subramaniyan P 137957f 52 M NEGATIVE 56 42
Subramani V 083006F 41 M NEGATIVE 25 41
Edi Mannan M 089521f 36 M NEGATIVE 65 12
David r 822251 d 40 M NEGATIVE 46 34
Muthu Kanan 791698c 66 M NEGATIVE 114 78
Padam Priya 052650 C 33 F NEGATIVE 25 38
Jeya kumar 564871a 53 M NEGATIVE 31 22
 Yogesh S 550718c 12 M POSITIVE 39 39
Nandhini b 964713 d 19 F POSITIVE 28 39
DNA0 log10 DNA1 log DNA2 LOG2 DNA3 LOG3
3,000 3.48 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
2,000 3.30 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
20,000 4.30 0 1.00 #NULL! #NULL! #NULL! #NULL!
4,000,000 6.60 62 1.79 #NULL! #NULL! #NULL! #NULL!
3,000 3.48 23 1.36 #NULL! #NULL! #NULL! #NULL!
2,000,000 6.30 41 1.61 0 1.00 #NULL! #NULL!
3,000,000 6.48 47 1.67 0 #NULL! #NULL! #NULL!
2,000,000 6.30 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
1,000 3.00 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
2,000,000 6.30 0 1.00 #NULL! #NULL! #NULL! #NULL!
30,000,000 7.48 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
4,000,000 6.60 42 1.62 80,000 4.90 #NULL! #NULL!
3,000,000 6.48 136 2.13 16 1.20 #NULL! #NULL!
5,000 3.70 0 1.00 0 1.00 #NULL! #NULL!
5,000 3.70 10 1.00 0 1.00 #NULL! #NULL!
400,000,000 8.60 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
100,000 5.00 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
########## 9.48 8,000 3.90 40,000 4.60 #NULL! #NULL!
########## 9.90 4,000 3.60 410 2.61 #NULL! #NULL!
300,000,000 8.48 4,000 3.60 50 1.70 #NULL! #NULL!
########## 9.30 100,000 5.00 #NULL! #NULL! #NULL! #NULL!
119 2.08 0 1.00 #NULL! #NULL! #NULL! #NULL!
5,000 3.70 466 2.67 #NULL! #NULL! #NULL! #NULL!
419 2.62 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
2,000,000 6.30 62 1.79 0 #NULL! 0 1.00
50,000 4.70 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
2,000 3.30 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
31 1.49 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
60,000 4.78 10 1.00 0 1.00 10 1.00
10,000,000 7.00 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
900,000 5.95 1,000,000 6.00 349 2.54 #NULL! #NULL!
20,000 4.30 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
20,000,000 7.30 43 1.63 #NULL! #NULL! #NULL! #NULL!
10,000 4.00 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
100,000,000 8.00 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
60,000,000 7.78 8,000,000 6.90 1,000,000 6.00 10,000,000 7.00
4,000,000 6.60 10,000,000 7.00 60,000 4.78 900,000 5.95
3,000 3.48 30,000 4.48 569 2.76 0 1.00
60,000 4.78 28 1.45 3,000 3.48 #NULL! #NULL!
300,000 5.48 30,000 4.48 60,000 4.78 #NULL! #NULL!
40,000,000 7.60 50,000,000 7.70 #NULL! #NULL! #NULL! #NULL!
4,000,000 6.60 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
4,000 3.60 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
20,000 4.30 31 1.49 #NULL! #NULL! #NULL! #NULL!
900,000,000 8.95 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
170 2.23 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
14 1.15 10 1.00 #NULL! #NULL! #NULL! #NULL!
57 1.76 0 1.00 #NULL! #NULL! #NULL! #NULL!
80,000,000 7.90 10,000 4.00 #NULL! #NULL! #NULL! #NULL!
200,000 5.30 20,000 4.30 #NULL! #NULL! #NULL! #NULL!
400,000 5.60 0 1.00 #NULL! #NULL! #NULL! #NULL!
2,000,000 6.30 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
2,000,000 6.30 17 1.23 11 1.04 32 1.51
30,000,000 7.48 483 2.68 140 2.15 #NULL! #NULL!
1,000,000 6.00 0 1.00 0 1.00 #NULL! #NULL!
10,000 4.00 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
2,000 3.30 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
400,000 5.60 6,000 3.78 12 1.08 10 1.00
268 2.43 41 1.61 10 1.00 #NULL! #NULL!
40,000 4.60 1,000,000 6.00 #NULL! #NULL! #NULL! #NULL!
2,000 3.30 0 1.00 #NULL! #NULL! #NULL! #NULL!
7,000 3.85 0 1.00 #NULL! #NULL! #NULL! #NULL!
5,000,000 6.70 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
5,000,000 6.70 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
200,000,000 8.30 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
200,000,000 8.30 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
2,000 3.30 69 1.84 24 1.38 #NULL! #NULL!
2,000 3.30 68 1.83 #NULL! #NULL! #NULL! #NULL!
300,000,000 8.48 1,000 3.00 #NULL! #NULL! #NULL! #NULL!
10,000 4.00 16 1.20 #NULL! #NULL! #NULL! #NULL!
500,000,000 8.70 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
2,000,000 6.30 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
80,000 4.90 10 1.00 #NULL! #NULL! #NULL! #NULL!
242 2.38 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
300,000,000 8.48 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
500,000 5.70 117 2.07 31 1.49 #NULL! #NULL!
3,000 3.48 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
10,000 4.00 100,000 5.00 10 1.00 0 1.00
########## 9.00 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
40,000 4.60 709 2.85 200 2.30 17 1.23
2,000 3.30 0 1.00 #NULL! #NULL! #NULL! #NULL!
43 1.63 0 1.00 #NULL! #NULL! #NULL! #NULL!
10,000,000 7.00 20,000 4.30 850 2.93 26 1.41
147 2.17 0 1.00 10 1.00 #NULL! #NULL!
100,000 5.00 0 1.00 #NULL! #NULL! #NULL! #NULL!
20,000 4.30 0 1.00 #NULL! #NULL! #NULL! #NULL!
400,000,000 8.60 7,000 3.85 773 2.89 2,000 3.30
70,000,000 7.85 10,000 4.00 #NULL! #NULL! #NULL! #NULL!
SAG0 LO0 SAG1 LO1 SAG2 LO2 SAG3 LO3
6,734 3.83 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
16,410 4.22 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
874 2.94 1,268 3.10 #NULL! #NULL! #NULL! #NULL!
2,757 3.44 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
20,883 4.32 18,919 4.28 #NULL! #NULL! #NULL! #NULL!
3,637 3.56 4,304 3.63 3,028 3.48 #NULL! #NULL!
3,300 3.52 6,130 3.79 2,880 3.46 #NULL! #NULL!
5,063 3.70 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
785 2.89 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
2,104 3.32 1,243 3.09 #NULL! #NULL! #NULL! #NULL!
7,209 3.86 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
16,338 4.21 13,832 4.14 9,323 3.97 #NULL! #NULL!
437 2.64 710 2.85 651 2.81 #NULL! #NULL!
5,388 3.73 7,905 3.90 5,242 3.72 #NULL! #NULL!
2,410 3.38 102 2.01 2,207 3.34 #NULL! #NULL!
250,000 5.40 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
783 2.89 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
88,379 4.95 110,818 5.04 50,039 4.70 #NULL! #NULL!
250,000 5.40 57,739 4.76 #NULL! #NULL! #NULL! #NULL!
54,903 4.74 28,841 4.46 40,887 4.61 #NULL! #NULL!
173,345 5.24 110,511 5.04 #NULL! #NULL! #NULL! #NULL!
266 2.43 145 2.16 #NULL! #NULL! #NULL! #NULL!
16,146 4.21 18,094 4.26 #NULL! #NULL! #NULL! #NULL!
7,344 3.87 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
1,954 3.29 952 2.98 667 2.82 956 2.98
1,797 3.25 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
2,803 3.45 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
13,198 4.12 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
1,804 3.26 844 2.93 1,501 3.18 1,737 3.24
21,297 4.33 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
426 2.63 231 2.36 1,456 3.16 #NULL! #NULL!
60,704 4.78 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
23,208 4.37 19,831 4.30 #NULL! #NULL! #NULL! #NULL!
31,265 4.50 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
8,778 3.94 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
250,000 5.40 23,134 4.36 1,941 3.29 6,616 3.82
2,464 3.39 7,427 3.87 2,517 3.40 2,006 3.30
7,392 3.87 34,834 4.54 28,029 4.45 12,842 4.11
7,287 3.86 28,845 4.46 14,923 4.17 #NULL! #NULL!
949 2.98 34,834 4.54 2,006 3.13 #NULL! #NULL!
24,929 4.40 22,831 4.36 #NULL! #NULL! #NULL! #NULL!
98 1.99 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
9,373 3.97 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
1,374 3.14 4,053 3.61 #NULL! #NULL! #NULL! #NULL!
40,082 4.60 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
25 1.40 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
5,232 3.72 3,811 3.58 #NULL! #NULL! #NULL! #NULL!
33,633 4.53 44,190 4.65 #NULL! #NULL! #NULL! #NULL!
69,268 4.84 104,239 5.02 #NULL! #NULL! #NULL! #NULL!
60,058 4.78 83,662 4.92 #NULL! #NULL! #NULL! #NULL!
23,520 4.37 33,994 4.53 #NULL! #NULL! #NULL! #NULL!
32,222 4.51 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
10,935 4.04 14,435 4.16 14,605 4.16 17,106 4.23
34,788 4.54 124 2.09 2 0.26 #NULL! #NULL!
5,532 3.74 5,452 3.74 #NULL! #NULL! #NULL! #NULL!
2,343 3.37 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
8,654 3.94 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
23,338 4.37 49,078 4.69 44,246 4.65 #NULL! #NULL!
3,117 3.49 2 0.35 3 0.41 #NULL! #NULL!
1,966 3.29 2,814 3.45 #NULL! #NULL! #NULL! #NULL!
23,991 4.38 28,629 4.46 #NULL! #NULL! #NULL! #NULL!
3,605 3.56 2,114 3.33 #NULL! #NULL! #NULL! #NULL!
924 2.97 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
1,925 3.28 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
47,914 4.68 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
82,065 4.91 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
19,860 4.30 19,454 4.29 20,387 4.31 #NULL! #NULL!
6,930 3.84 2,008 3.30 #NULL! #NULL! #NULL! #NULL!
250,000 5.40 60,462 4.78 #NULL! #NULL! #NULL! #NULL!
11,128 4.05 24,377 4.39 #NULL! #NULL! #NULL! #NULL!
9,631 3.98 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
10,777 4.03 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
114,350 5.06 40,282 4.61 #NULL! #NULL! #NULL! #NULL!
2,583 3.41 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
125,000 5.10 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
13,135 4.12 17,293 4.24 8,815 3.95 #NULL! #NULL!
38,403 4.58 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
858 2.93 1,298 3.11 1,236 3.09 1,109 3.04
116,818 5.07 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
14,524 4.16 21,269 4.33 11,472 4.06 11,472 4.06
3 0.41 3 0.42 #NULL! #NULL! #NULL! #NULL!
2 0.19 2 0.19 #NULL! #NULL! #NULL! #NULL!
24,886 4.40 38,012 4.58 23,715 4.38 38,012 4.58
8,446 3.93 6,396 3.81 8,446 3.93 #NULL! #NULL!
15,020 4.18 24,970 4.40 #NULL! #NULL! #NULL! #NULL!
25,712 4.41 20,903 4.32 #NULL! #NULL! #NULL! #NULL!
250,000 5.40 240,256 5.38 95,214 4.98 #NULL! #NULL!
27,047 4.43 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
USG BIOPSY CLINICAL DRUG VAR00001
0   ETV 1.00
0   ETV 1.00
0  ENH ETV 1.00
0  CLD ETV 1.00
1  ENH + CLD ETV 1.00
1  IR ETV 1.00
1  CLD ETV 1.00
0   ETV 1.00
0   ETV 1.00
1  ENH + CLD ETV 1.00
1   ETV 1.00
0  ENH ETV 1.00
0  ENH ETV 1.00
0  ENH + CLD ETV 1.00
0   ETV 1.00
0   ETV 1.00
0   ETV 1.00
0  IR ETV 1.00
0  IT ETV 1.00
0  IR ETV 1.00
0  IT ETV 1.00
1  LR + CLD ETV 1.00
1  IR = CLD ETV 1.00
1   ETV 1.00
0  LR + CLD ETV 1.00
1   ETV 1.00
1   ETV 1.00
1   ETV 1.00
1  ENH + CLD ETV 1.00
0   ETV 1.00
0  IR ETV 1.00
0   ETV 1.00
0  ENH ETV 1.00
0   IFN 3.00
0   IFN 3.00
0  IR IFN 3.00
0  IR IFN 3.00
0  IR IFN 3.00
0  IR IFN 3.00
1   IFN 3.00
0  IT IFN 3.00
0   LAM #NULL!
1   LAM #NULL!
1  ENH + CLD LAM #NULL!
0   LAM #NULL!
0   LAM #NULL!
0 mild steatosis with portal a lobularinfl LR LAM #NULL!
0  LR LAM #NULL!
0  IT LAM/ADF #NULL!
0 HAI 4/18 MILD PORTALFIBROSIS 2/6 ENH TDF 2.00
0  ENH TDF 2.00
0   TDF 2.00
1  CLD TDF 2.00
1  IR TDF 2.00
1  IR + CLD TDF 2.00
0   TDF 2.00
0   TDF 2.00
0  ENH TDF 2.00
1   TDF 2.00
1  ENH TDF 2.00
1   TDF 2.00
1  ENH + CLD TDF 2.00
1   TDF 2.00
1   TDF 2.00
0   TDF 2.00
0   TDF 2.00
0   TDF 2.00
0  IR + CLS TDF 2.00
0  IR TDF 2.00
1   TDF 2.00
1   TDF 2.00
0   TDF 2.00
0  IT TDF 2.00
1   TDF 2.00
0   TDF 2.00
1  IR + CLD TDF 2.00
0   TDF 2.00
0 HAI-5/18, EARLY PORTAL FIBROSIS ENH TDF 2.00
1   TDF 2.00
1  ENH + CLD TDF 2.00
1  ENH + CLD TDF 2.00
1  LR + CLD TDF 2.00
0  ENH TDF 2.00
0   TDF 2.00
0  ENH TDF 2.00
0  ENH TDF 2.00
0  IT TDF 2.00
0   TDF 2.00
remarks AST1 ALT1 AST2 ALT2 COMPLIANCERENALFAILUREAST3
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 26 10 #NULL! #NULL!   #NULL!
 23 26 #NULL! #NULL!   #NULL!
 25 24 #NULL! #NULL!   #NULL!
 105 143 58 79   #NULL!
 38 31 33 30   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 64 29 #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 #NULL! 48 33 28   #NULL!
 36 57 27 25   #NULL!
 29 49 43 78   #NULL!
 57 47 29 18   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 29 31 24 32   #NULL!
 37 29 27 21   #NULL!
 81 143 24 16   #NULL!
 #NULL! 27 #NULL! #NULL!   #NULL!
 27 14 #NULL! #NULL!   #NULL!
 60 47 #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 27 23 27 29   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 44 42 38 39   30
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 29 34 26 34  NO #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 27 38 #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 152 277 32 33 GOOD NO 29
 52 75 47 33 GOOD NO #NULL!
 54 91 72 151 GOOD NO 41
 #NULL! 9 #NULL! 223   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 #NULL! 34 #NULL! #NULL! POOR NO #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 144 95 #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 24 14 #NULL! #NULL!   #NULL!
ALL PT. #NULL! #NULL! #NULL! #NULL!   #NULL!
 24 16 #NULL! #NULL!   #NULL!
 18 12 #NULL! #NULL!   #NULL!
 #NULL! 23 #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 28 31 35 46   44
 39 25 60 24   61
 36 45 #NULL! #NULL!   #NULL!
 81 30 #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
reac 326 574 50 56   #NULL!
 #NULL! #NULL! 70 37   #NULL!
 41 35 #NULL! #NULL!   #NULL!
 #NULL! 37 #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 25 28 #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 29 33 30 38   #NULL!
 63 50 #NULL! #NULL!   #NULL!
 53 36 #NULL! #NULL!   #NULL!
 29 35 #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 28 20 #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 37 23 29 16   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 60 98 22 16 GOOD NO #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 56 42 52 39   38
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 31 20 #NULL! #NULL!   #NULL!
 41 51 #NULL! 27   #NULL!
 42 #NULL! #NULL! #NULL!   #NULL!
 19 20 #NULL! #NULL!   #NULL!
 20 19 #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
 #NULL! #NULL! #NULL! #NULL!   #NULL!
ALT3 a d Therapy VR EAg vcr Ethnicity
#NULL! #NULL! #NULL! #NULL! #NULL! 0.00 #NULL! bangladesh
#NULL! #NULL! #NULL! #NULL! #NULL! 0.00 #NULL! bangladesh
#NULL! 5.00 2.17 #NULL! 1.00 0.00 1.00 Bangladesh
#NULL! 5.00 2.17 #NULL! 1.00 0.00 0.00 Bangladesh
#NULL! 5.00 2.17 #NULL! 1.00 0.00 0.00 east
#NULL! 5.00 2.17 #NULL! 1.00 1.00 0.00 east
#NULL! 5.00 2.17 #NULL! 1.00 1.00 0.00 east
#NULL! #NULL! #NULL! #NULL! #NULL! 0.00 #NULL! east
#NULL! #NULL! #NULL! #NULL! #NULL! 0.00 #NULL! east
#NULL! 5.00 2.17 #NULL! 1.00 0.00 1.00 East
#NULL! #NULL! #NULL! #NULL! #NULL! 1.00 #NULL! East
#NULL! 5.00 2.17 #NULL! 1.00 0.00 0.00 East
#NULL! 5.00 2.17 #NULL! 1.00 0.00 0.00 East
#NULL! 5.00 2.17 #NULL! 1.00 0.00 1.00 East
#NULL! 5.00 2.17 #NULL! 1.00 0.00 1.00 East
#NULL! #NULL! #NULL! #NULL! #NULL! 1.00 #NULL! East
#NULL! #NULL! #NULL! #NULL! #NULL! 1.00 #NULL! East
#NULL! 5.00 2.17 #NULL! 1.00 1.00 0.00 East
#NULL! 5.00 2.17 #NULL! 1.00 1.00 0.00 East
#NULL! 5.00 2.17 #NULL! 1.00 1.00 0.00 East
#NULL! 5.00 2.17 #NULL! 1.00 1.00 0.00 East
#NULL! 5.00 2.17 #NULL! 1.00 0.00 1.00 North
#NULL! 5.00 2.17 #NULL! 0.00 1.00 0.00 north east
#NULL! #NULL! #NULL! #NULL! #NULL! 1.00 #NULL! North east
#NULL! 5.00 2.17 #NULL! 1.00 0.00 0.00 North east
#NULL! #NULL! #NULL! #NULL! #NULL! 0.00 #NULL! North East
#NULL! #NULL! #NULL! #NULL! #NULL! 0.00 #NULL! North East
#NULL! #NULL! #NULL! #NULL! #NULL! 0.00 #NULL! North East
31 5.00 2.17 #NULL! 1.00 0.00 1.00 North East
#NULL! #NULL! #NULL! #NULL! #NULL! 0.00 #NULL! south
#NULL! 5.00 2.17 #NULL! 0.00 0.00 0.00 south
#NULL! #NULL! #NULL! #NULL! #NULL! 1.00 #NULL! south
#NULL! 5.00 2.17 #NULL! 1.00 0.00 0.00 South
#NULL! #NULL! #NULL! #NULL! #NULL! 1.00 #NULL! East
#NULL! #NULL! #NULL! #NULL! #NULL! 1.00 #NULL! East
44 5.00 2.17 #NULL! 0.00 1.00 0.00 East
#NULL! 5.00 2.17 #NULL! 0.00 1.00 0.00 East
86 5.00 2.17 #NULL! 0.00 1.00 0.00 East
#NULL! 5.00 2.17 #NULL! 1.00 1.00 0.00 East
#NULL! #NULL! #NULL! #NULL! #NULL! 1.00 #NULL! South
#NULL! 5.00 2.17 #NULL! 0.00 1.00 0.00 South
#NULL! #NULL! #NULL! #NULL! #NULL! 0.00 #NULL! east
#NULL! #NULL! #NULL! #NULL! #NULL! 0.00 #NULL! East
#NULL! 5.00 2.17 #NULL! 1.00 0.00 0.00 East
#NULL! #NULL! #NULL! #NULL! #NULL! 1.00 #NULL! East
#NULL! #NULL! #NULL! #NULL! #NULL! 0.00 #NULL! north east
#NULL! 5.00 2.17 #NULL! 0.00 0.00 1.00 south
#NULL! 5.00 2.17 #NULL! 1.00 0.00 1.00 South
#NULL! 5.00 2.17 #NULL! 1.00 1.00 0.00 South
#NULL! 5.00 2.17 #NULL! 0.00 0.00 0.00 Bangladesh
#NULL! 5.00 2.17 #NULL! 1.00 0.00 1.00 Bangladesh
#NULL! #NULL! #NULL! #NULL! #NULL! 1.00 #NULL! Bangladesh
63 5.00 2.17 #NULL! 1.00 1.00 0.00 east
42 5.00 2.17 #NULL! 1.00 1.00 0.00 east
#NULL! 5.00 2.17 #NULL! 1.00 1.00 1.00 east
#NULL! #NULL! #NULL! #NULL! #NULL! 0.00 #NULL! east
#NULL! #NULL! #NULL! #NULL! #NULL! 0.00 #NULL! east
#NULL! 5.00 2.17 #NULL! 0.00 0.00 0.00 east
#NULL! 5.00 2.17 #NULL! 0.00 0.00 0.00 East
#NULL! 5.00 2.17 #NULL! 0.00 0.00 0.00 East
#NULL! 5.00 2.17 #NULL! 1.00 0.00 1.00 East
#NULL! 5.00 2.17 #NULL! 1.00 0.00 1.00 East
#NULL! #NULL! #NULL! #NULL! #NULL! 1.00 #NULL! East
#NULL! #NULL! #NULL! #NULL! #NULL! 1.00 #NULL! East
#NULL! #NULL! #NULL! #NULL! #NULL! 1.00 #NULL! East
#NULL! #NULL! #NULL! #NULL! #NULL! 1.00 #NULL! East
#NULL! 5.00 2.17 #NULL! 0.00 1.00 0.00 East
#NULL! 5.00 2.17 #NULL! 0.00 1.00 0.00 East
#NULL! 5.00 2.17 #NULL! 1.00 1.00 0.00 East
#NULL! 5.00 2.17 #NULL! 1.00 0.00 0.00 North
#NULL! #NULL! #NULL! #NULL! #NULL! 1.00 #NULL! North
#NULL! #NULL! #NULL! #NULL! #NULL! 1.00 #NULL! North east
#NULL! 5.00 2.17 #NULL! 1.00 1.00 1.00 North east
#NULL! #NULL! #NULL! #NULL! #NULL! 0.00 #NULL! North East
#NULL! #NULL! #NULL! #NULL! #NULL! 1.00 #NULL! North East
#NULL! 5.00 2.17 #NULL! 1.00 1.00 0.00 south
#NULL! #NULL! #NULL! #NULL! #NULL! 0.00 #NULL! south
#NULL! 5.00 2.17 #NULL! 0.00 0.00 0.00 south
#NULL! #NULL! #NULL! #NULL! #NULL! 0.00 #NULL! South
30 5.00 2.17 #NULL! 0.00 0.00 0.00 South
#NULL! 5.00 2.17 #NULL! 1.00 0.00 1.00 South
#NULL! 5.00 2.17 #NULL! 1.00 0.00 1.00 South
#NULL! 5.00 2.17 #NULL! 1.00 0.00 0.00 South
#NULL! 5.00 2.17 #NULL! 1.00 0.00 1.00 South
#NULL! 5.00 2.17 #NULL! 1.00 0.00 1.00 South
#NULL! 5.00 2.17 #NULL! 1.00 0.00 1.00 South
#NULL! 5.00 2.17 #NULL! 1.00 1.00 0.00 South
#NULL! #NULL! #NULL! #NULL! 1.00 1.00 0.00 South
Followup nonresponse filter_$
#NULL! #NULL! #NULL!
#NULL! #NULL! #NULL!
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! #NULL! #NULL!
#NULL! #NULL! #NULL!
#NULL! 0.00 0
#NULL! #NULL! #NULL!
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! #NULL! #NULL!
#NULL! #NULL! #NULL!
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! #NULL! #NULL!
#NULL! 0.00 0
#NULL! #NULL! #NULL!
#NULL! #NULL! #NULL!
#NULL! #NULL! #NULL!
#NULL! 0.00 0
#NULL! #NULL! #NULL!
#NULL! 1.00 1
#NULL! #NULL! #NULL!
#NULL! 0.00 0
#NULL! #NULL! #NULL!
#NULL! #NULL! #NULL!
#NULL! 1.00 1
#NULL! 1.00 1
#NULL! 1.00 1
#NULL! 0.00 0
#NULL! 1.00 1
#NULL! 1.00 1
#NULL! #NULL! #NULL!
#NULL! #NULL! #NULL!
#NULL! 0.00 0
#NULL! #NULL! #NULL!
#NULL! #NULL! #NULL!
#NULL! 1.00 1
#NULL! 1.00 1
#NULL! 0.00 0
#NULL! 1.00 1
#NULL! 0.00 0
#NULL! #NULL! #NULL!
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! #NULL! #NULL!
#NULL! #NULL! #NULL!
#NULL! 0.00 0
#NULL! 1.00 1
#NULL! 1.00 1
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! #NULL! #NULL!
#NULL! #NULL! #NULL!
#NULL! #NULL! #NULL!
#NULL! #NULL! #NULL!
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! #NULL! #NULL!
#NULL! #NULL! #NULL!
#NULL! 0.00 0
#NULL! #NULL! #NULL!
#NULL! #NULL! #NULL!
#NULL! 0.00 0
#NULL! #NULL! #NULL!
#NULL! 1.00 1
#NULL! #NULL! #NULL!
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! 1.00 1
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! 0.00 0
#NULL! 0.00 0
